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Involvement of Adenosine A1 receptors in systemic inflammation and altered 
vascular reactivity in allergic mice 
 
Dovenia S. Ponnoth 
 
 
Epidemiological studies have established that people who have lung diseases such 
as asthma and COPD are likely to develop adverse cardiovascular events. While the 
reason for this has not been elucidated, it is believed that inflammation could be the key 
component linking the two conditions. Adenosine, an endogenous purine nucleoside, has 
been strongly implicated in asthma pathophysiology and also has potent effects on the 
cardiovascular system. This work was undertaken to gain a better understanding of the 
relationship between asthma and its cardiovascular effects, and more specifically the 
possible role adenosine plays under these conditions.  
We hypothesize that asthmatic lung inflammation translates into systemic 
inflammation and alters vascular responses where adenosine plays an important role. 
Therefore, this study investigated the effects of aerosolized adenosine, used to elevate 
lung adenosine levels, on vascular reactivity and inflammation in a well established 
mouse model of allergic asthma established in our lab. We found that allergic mice had 
poor vasorelaxation to adenosine and systemic inflammation, in addition to lung 
inflammation, and aerosolized adenosine exacerbated these effects. Data indicated a 
possible role for A1 adenosine receptor (AR) in altered vascular reactivity and 
inflammation. Based on these findings, we next studied the effects of adenosine using 
genetically modified mice in which the A1 AR gene was deleted (A1KO) and 
corresponding A1 wild-type(A1WT) mice, in which the A1 receptor was present. 
Allergic A1KO mice had no systemic inflammation, and the adenosine-mediated 
vasorelaxation responses obtained were comparable to non-allergic mice. Aerosolized 
adenosine also did not have any effect in A1KO mice. On the other hand, allergic A1WT 
mice had lower aortic relaxation response to non-selective adenosine analog NECA, 
presence of significantly higher levels of inflammatory cytokines in plasma and higher 
airway responsiveness to NECA, compared to non-allergic A1WT controls and all groups 
of A1KO mice, with aerosolized adenosine exacerbating all these responses.  From these 
data, it can be concluded that asthmatic mice had poor vascular responses and 
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Adenosine is an endogenous purine nucleoside with multiple physiological effects 
and is produced by all cells. Figure 1.1 shows the chemical structure of adenosine. Some 
of its regulatory activities are vasodilation of the coronary vessels, including under 
ischemic conditions, neuromodulation especially in the sleep-wake cycle, effects on the 
heart including regulating inotropy, chronotropy and many others (Fredholm, 2007).  
Generation of adenosine and its metabolism 
Under normal physiological conditions, adenosine is formed by the intracellular 
conversion of S-adenosyl-L methionine (SAM) to S-adenosyl-L-homocysteine (SAH). 
This moiety is then converted to adenosine and homocysteine by SAH-hydrolase 
(Deussen et al., 1989; Pelleg and Porter, 1990). Adenosine can also be produced 
extracellulary through successive dephosphorylation of ATP; ATP is dephosphorylated to 
ADP and then AMP which is converted to adenosine via ecto-5’-nucleotidases 
(Bardenheuer and Schrader, 1986; Forsythe and Ennis, 1999). Adenosine thus produced 
can be further converted to inosine by the enzyme adenosine deaminase (ADA) and 
finally is broken down to uric acid which is excreted in urine. There is another pathway 
through which adenosine is re-converted to AMP via the enzyme adenosine kinase (AK). 
In addition to being metabolized, adenosine can also act on specific receptors to induce 
various physiological effects. Figure 1.2 shows the metabolic processes of adenosine 
production and breakdown. Extra-cellular concentrations of adenosine are elevated 
several fold during periods of increased metabolic demand, injury or stress such as 
ischemia (Sparks and Bardenheuer, 1986).  
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Adenosine produces various effects through cell surface purinergic receptors and 
thus far, 4 subtypes have been identified: A1, A2A, A2B and A3.  All four receptors are G-
protein coupled and the effects that adenosine produces depends on both the receptor 
subtype that is activated as well as the organ/tissue in which the receptor is present. A1 
and A3 receptors are coupled to Gi while the A2A and A2B receptors are coupled to Gs.  A1 
and A2A have a high affinity for adenosine, while the A2B and A3 receptors are considered 
to be low affinity. The A1 receptor signals through Gi/o G-proteins and its activation leads 
to an inhibition of adenylyl cyclase (AC) which causes a lowering of cyclic AMP 
(cAMP) levels. Signaling through the A1 receptor can also lead to activation of IP3/DAG 
through the PLC pathway (Tawfik et al., 2005). The A2A receptor signals through the Gs 
pathway and its activation leads to stimulation of AC resulting in increased production of 
cAMP. Activation of theA2A receptor produces mainly anti-inflammatory effects and this 
receptor is involved in coronary vasodilation. The A2B receptor signals through Gs/q and 
its activation can either result in increased cAMP or IP3/DAG and Ca2+ levels. Lastly, the 
A3 receptor signals through Gi and is negatively coupled to AC.  
 
Asthma 
As previously mentioned, adenosine has varied effects. Of particular interest to 
this work is the role of adenosine in asthma. Asthma is a chronic lung disease 
characterized by inflammation and bronchoconstriction. There is a growing incidence of 
asthma in the U.S. such that many experts believe the country is in the midst of an asthma 
epidemic. Although there are many treatment options available to manage symptoms, 
there is no cure for this disease. Over 20 million people have been diagnosed with 
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asthma, with 9 million under the age of 18 years; children are particularly susceptible. 
Allergic asthma accounts for about half of these numbers. Several hypotheses have been 
put forward to explain the growing asthma epidemic including the hygiene hypothesis 
and genetic predisposition.   
The disease consists of episodic events which manifest as hyper-responsiveness of 
the airways to common triggers like dust, pollen, cold air, cigarette smoke and other 
pollutants, resulting in bronchospasm and difficulty in breathing. It can also be induced 
by exercise and inhalation of cold air. Airway obstruction occurs due to inflammation, 
excessive mucus production, and hyperreactive bronchial smooth muscle. As a 
consequence, hypoxemia secondary to hypoventilation is present.  Severe acute asthmatic 
episodes can be life-threatening and require urgent care. Failure to treat prolonged 
respiratory failure can result in death. Initially, the inflammation observed in asthma is 
acute in nature but eventually becomes chronic with the progression of the disease, and 
long term effects of asthma are linked its inflammatory component. Disease management 
consists of anti-inflammatory drugs and bronchodilators.  
 
Adenosine and asthma 
Adenosine has long been implicated in the pathogenesis of asthma. Inhalation of 
adenosine was shown to be a potent bronchoprovocant in asthmatic patients (Cushley et 
al., 1983). This was one of the first studies to demonstrate a role for adenosine in asthma 
and it established that guanosine, another purine nucleoside, did not have the same effect.  
Inosine, the deaminated adenosine metabolite, did not produce bronchoconstriction 
(Mann et al., 1986b), suggesting that the effect on bronchial smooth muscle was specific 
to adenosine and possibly involved adenosine receptors. Asthmatic patients also had 
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significantly higher levels of adenosine in bronchoalveolar lavage fluid (BAL) and 
exhaled breath condensate than normal healthy subjects (Driver et al., 1993; Huszar et al., 
2002). Adenosine can also have indirect effects in the lungs; it causes degranulation of 
mast cells which leads to the release of histamine and subsequent cascade of events 
including H1-receptor-mediated bronchoconstriction and inflammatory response (Fozard 
and Hannon, 2000; Oldenburg and Mustafa, 2005).  This mast-cell mediated response is 
believed to occur through the A2B receptor although this has not been conclusively 
proven (Zhong et al., 2003).  
Studies done using mice lacking the ADA enzyme have shown that these mice 
have large amounts of adenosine in their lungs and severe lung inflammation (Blackburn 
et al., 2000). In fact, these mice were unable to survive beyond three weeks due to 
respiratory distress. Further studies using ADA deficient mice demonstrated the presence 
of eosinophilia in the lungs and periphery, extensive mast cell degranulation and 
increased levels of serum IgE (Zhong et al., 2001). There is evidence that adenosine 
causes recruitment of inflammatory cells to the lung (Fan and Mustafa, 2002) and 
amplification of the inflammatory response (Spicuzza et al., 2006).  Despite all of these 
data linking adenosine to asthma, the exact extent of adenosine implication and specific 








Reactive airway diseases and cardiovascular complications 
An interesting facet noted in epidemiological studies is that people suffering from 
asthma, chronic obstructive pulmonary disease (COPD) and reactive airway diseases are 
at an increased risk for developing cardiovascular disease (CVD) (Gan et al., 2004; 
Schanen et al., 2005; Sin and Man, 2005). There is an association between atherosclerosis 
and stroke with reactive airway diseases. One study found that adult-onset asthma was 
associated with increased carotid atherosclerosis in women (Onufrak et al., 2007). Many 
studies have shown that impaired lung function is a risk factor for CVD (Tockman et al., 
1995). Bronchial hyperresponsiveness to methacholine is associated with increased 
carotid intima-media thickness (Zureik et al., 2004). One of the leading causes for 
hospitalizations and deaths occurring in COPD patients is cardiovascular events (Sidney 
et al., 2005).  
Inflammation is a key event in CVD and several inflammatory mediators and 
markers are associated with it, including C-reactive protein (CRP), plasma fibrinogen, 
leucocytes, and interleukins (IL-1β, -4, -5, -6, -8 and -13). CRP has been implicated in 
atherosclerosis, and levels of this protein are elevated in this condition. The level of CRP 
is considered one of the best predictors of the risk of CVD (Yudkin et al., 1999; Pearson 
et al., 2003). Interleukins, in particular IL-6 (Yudkin et al., 2000), are also important 
markers of CVD. 
Recent evidence in animal models indicates that CV complications associated 
with asthma are independent of asthma therapy and could be a result of asthma itself. 
Myocardial ischemia-reperfusion injury was enhanced in a rabbit model of systemic 
allergy and asthma (Hazarika et al., 2004) and allergic inflammation in the airways 
 8
enhanced neutrophil recruitment to the myocardium and severity of ischemia-reperfusion 
in a murine model (Hazarika, 2005).  
Asthma thus, is a risk factor for cardiovascular disease.  However, its potential as 
a risk factor in CVD has not been widely studied with respect to mechanisms underlying 
the phenomenon, nor have the effects of adenosine been explored on cardiovascular 
parameters in asthma. Work done in this dissertation attempts to shed light on both of 
these aspects. 
 
Animal models of asthma 
The use of animal models has been one of the mainstays for asthma research. Species 
including mice, rats, rabbits, guinea pigs, sheep and dogs amongst others have been used 
(Abraham et al., 1983; Muccitelli et al., 1987; de Weck et al., 1997; Liu et al., 2005). 
There are several advantages and disadvantages in employing animal models to study 
asthma. The principle criticism in using animal models of asthma is that none of the 
species develop the disease spontaneously nor exhibit the episodic airway hyper-
responsiveness of the disease that is characteristic of the human condition, i.e., it is not 
possible to reproduce the exact human disease in animals.  The asthma phenotype 
generated in animal models is a Th-2 type response with acute inflammation and 
increased responsiveness to bronchoprovocants observed.  The main advantage to using 
animal models is the ability to study intact systems and carrying out in vivo experiments. 
Many of these models are also cost effective and a number of species specific probes 
have been developed which aid greatly in research. For mechanistic purposes, animal 
models are extremely useful and also for drug screening purposes.  
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Murine models of asthma 
Mice are very commonly used to study asthma, especially for modeling allergic 
responses in the airways and lungs. With the increasing number of genetically modified 
mice available, these are ideal tools for studying specific aspects of the disease.  There 
are knock-out mice for all four adenosine receptors as well as mice in which ADA has 
been knocked out and double knock-outs with specific adenosine receptors. Mice in 
which specific cytokines have been knocked out are also available to study inflammatory 
signaling with respect to asthma. These include IL-13 knock out mice which exhibit a 
lack of airway remodeling characteristic of asthma (Kumar et al., 2002). One of the main 
advantages of using mice to duplicate certain asthmatic features is the ease of various 
tools with which allergic models can be developed and also the easy availability and cost 
effectiveness of such models. Mice can be sensitized to various antigens including dust-
mite (O'Brien et al., 1996), (Johnson et al., 2004), ragweed extracts (Oldenburg and 
Mustafa, 2005; Fan and Jamal Mustafa, 2006), and one of the more commonly used 












Purpose and Project Summary 
The purpose of this investigation is to understand the effects of asthma beyond the lungs, 
specifically to determine if there is any alteration in vascular reactivity. Since adenosine 
has major implications in both asthma and on the vasculature, it is important to elucidate 
the adenosine-mediated systemic and vascular effects in asthma. Lastly, identifying the 
possible adenosine receptor(s) involved in inflammatory and other changes would be able 
to provide further insights in understanding the profound and diverse effects of adenosine 
in asthma. Determining which receptor is involved in the vascular changes is necessary 
for developing potential therapeutic approaches to asthma, particularly with respect to 
targeting and reducing the commonly reported adverse vascular effects that are a 
consequence with asthma. With this in mind, the following aims were developed: 
 
 Aim 1: Identify markers of systemic and local arterial inflammation in an allergic 
murine model of asthma.  
Hypotheses  
(a):  Chronic inflammatory disease of the airway and lung leads to an increase in 
systemic levels of several inflammatory mediators including TNF-α, IL-1β, IL-4, and IL-
13    
(b) Chronic inflammatory disease of the airway and lung can lead to local inflammation 





Aim 2: Characterize the adenosine receptor sub-type(s) involved in altered vascular 
response and quantify their expression levels in our model of asthma.  
Hypotheses  
(a) Multiple adenosine receptors (A1, A2A, A2B, and A3) regulate vascular responses and 
are differentially activated in an allergic inflammatory model.  
(b) Specific adenosine receptor(s) (A1, A2A, A2B, A3) are either up-regulated or down-
regulated in asthma 
 
Aim 3: Identify the adenosine receptor subtype(s) involved in vascular inflammation. 
Hypothesis: The interaction between inflammatory mediators and adenosine through 




MATERIALS AND METHODS 
 
Mice 
Balb/c mice, 8-10 weeks old males were obtained from Harlan Sprague Dawley 
(Indianapolis, IN). To study vascular effects of A2A receptor-activation, A2A KO and WT 
mice were used which were initially obtained from Dr. Catherine Ledent, University of 
Brussels, Belgium and maintained as a breeding colony at WVU. Male and female mice 
aged 12-14 weeks were used for all A2A adenosine receptor experiments.  A1KO mice 
were kindly provided by Dr. Stephen Tilley, University of North Carolina, Chapel Hill 
and mice aged 8-12 weeks were used for experiments. All mice were kept in community 
cages with 12-hr periods of light and dark cycles and were maintained on a ragweed-free 
diet with access to water ad libitum. All animal care and experimentation used in this 
study were carried out under protocols approved by the Institutional Animal Care and 
Use Committee of West Virginia University (Animal Use Protocol # 05-0603 and #06-
1009); animal procedures were monitored by this committee and were done in 
accordance with the provisions of the NIH “Guide for the Care and Use of Laboratory 
Animals.” 
 
Animal sensitization protocol 
Sensitization of mice was performed according to the previously established 
protocols including one described from this laboratory (Fan and Mustafa, 2002; Fan et 
al., 2003; Oldenburg and Mustafa, 2005; Fan and Mustafa, 2006; Mustafa et al., 2007). 
This model of allergic asthma has been shown to develop airway inflammation and 
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airway hyper-reactivity to methacholine. In brief, mice were sensitized on days 1 and 6 
with i.p. injections of ragweed allergen (Greer Laboratories, Lenoir, NC), 200 µg per 
dose, with 200 µL Imject Alum (Pierce Laboratories, Rockford, IL). Non-sensitized 
control animals received only the Imject alum with the same volumes. Ten days after 
sensitization, the mice were placed in a Plexiglas chamber and challenged with 1% 
aerosolized ragweed or with 0.9% saline as a control, using an ultrasonic nebulizer 
(DeVilbiss, Somerset, PA) for 20 min both in the morning and afternoon for three 
consecutive days. The aerosolization of allergen was performed at a flow rate of 2 
mL/min, and the aerosol particles had a median aerodynamic diameter of less 4 µm 
(DeVilbiss).  
In addition, acute elevations in lung adenosine levels were produced 
experimentally by adenosine inhalation (6 mg/ml for 2 min on day 14) in one group of 
sensitized-challenged mice and one group of control mice to further enhance allergen-
induced effects. This dose was chosen based on previous studies in this model (Fan and 
Mustafa, 2002; Fan and Mustafa, 2006). The time frame for experiments was 24-hr post-
adenosine inhalation, chosen on the basis of an earlier study from this lab which showed 
maximum eosinophilic inflammation in airways after 24 hr of adenosine inhalation (Fan 
and Jamal Mustafa, 2006), which is a hallmark of asthmatic inflammation. Twenty-four 
hours after the last challenge, animals were sacrificed for collection of aorta and blood 






In-vitro organ bath: For vascular reactivity (aorta) 
Preparation of mouse isolated aorta and isometric force measurement 
Mice were sacrificed by anesthesia with pentabarbitol sodium (65 mg/kg, i.p.) 
followed by thoracotomy and removal of the aorta. This was then carefully cleaned to 
remove fat and connective tissue without damaging the tissue and was then cut 
transversely into 3-4 mm rings. The rings were mounted vertically between two stainless 
steel wire hooks and then suspended in 10 mL organ baths containing Krebs-Henseleit 
buffer. The Krebs-Henseleit buffer (pH 7.4) containing 118 mM NaCl, 4.8 mM KCl, 1.2 
mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 11 mM glucose and 2.5 mM CaCl2 was 
maintained at 37°C with continuous bubbling of 95% O2 and 5% CO2. For measurement 
of isometric force response, aortic rings were equilibrated for 90 min with a resting force 
of 1g (Tawfik et al., 2005; Ansari et al., 2007b) and change of the bathing solution at 15 
min interval. At the end of equilibration period, tissues were contracted twice with 50 
mM KCl to determine the contractility of individual aortic rings , which were washed out 
with Krebs-Henseleit buffer. Aortic rings were then constricted with phenylephrine (PE, 
10-7M) to obtain a steady contraction and changes in tension were monitored 
continuously with fixed range precision force transducer (TSD, 125 C, BIOPAC system) 
connected to the differential amplifier (DA 100B, BIOPAC system). The data were 
recorded using a MP100 digital acquisition system and analyzed using Acknowledge 
3.5.7 software (BIOPAC system). After equilibration, the responsiveness and stability of 
individual rings were checked by successive administration of a submaximally effective 
concentration of PE (10-7 M). The integrity of the vascular endothelium was assessed 
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pharmacologically by acetylcholine (ACh; 10-7 M) to produce relaxation of PE pre-
contracted rings. A relaxation of ≥50% with ACh was considered as normal. Aortic rings 
were then washed several times with Krebs-Henseleit solution, and allowed to equilibrate 
for 30 min before the experimental protocol began in which concentration-responsiveness 
to  various drugs was measured including NECA (non-selective adenosine analog; 10-11 -
10-5 M), adenosine (10-11 -10-4 M) and CGS 21860 (selective A2A agonist; 10-11 -10-6 M) 
were run parallel in aortic rings. In all cases, the drug was added to yield the next higher 
concentration only when the response to the earlier dose reached a steady state. In 
experiments where the effects of an antagonist were measured, it was added 30 min 
before contraction of the tissue with PE, and was present throughout the experiments. 
Contraction/relaxation responses were expressed as a percentage 
increase/decrease in the contraction with respect to PE (alone) in response to each 
concentration of agonist used. 
 
Airway responsiveness 
Airway hyperresponsiveness was measured by whole body plethysmography. 
Unrestrained mice were placed in Plexiglass chambers (Buxco Electronics, Wilmington, 
NC) and pressure fluctuations during ventilatory cycles were monitored by pressure 
transducers. Data was calculated in the form of enhanced pause (Penh) according to a 
previously described protocol (Hamelmann et al., 1997).  
Penh is a dimensionless index of airway obstruction, and higher the Penh value, 
the greater is the obstruction. The waveform (Hamelmann et al., 1997; Drazen et al., 
1999) describing the process of Penh calculation is shown in figure 2.1 and 
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mathematically, Penh is obtained by the following equation (Hamelmann et al., 1997; 
Drazen et al., 1999). 
Penh= PEF/PIF* (TE/Rt-1) 
PEF= Peak expiratory height 
PIF= Peak inspiratory height 
TE= Expiratory time 
Rt= Time to expire 65% of the volume 
Pause= (TE/RT)-1 



















Figure 2.1: Ventilatory cycle from whole body plethysmography. Te=expiratory time; 



















































ADENOSINE-MEDIATED ALTERATION OF VASCULAR REACTIVITY AND 
INFLAMMATION IN A MURINE MODEL OF ASTHMA 
American Journal of Physiology, May 2008 
(Used with permission from Am J Physiol Heart Circ Phsyiol) 
 
Abstract 
Chronic respiratory disorders such as asthma are believed to be associated with 
adverse cardiovascular events. We hypothesize that asthmatic inflammation translates 
into systemic inflammation and alters vascular responses where adenosine (AD) plays an 
important role. Therefore, this study investigated the effects of aerosolized AD, used to 
elevate lung AD levels, on vascular reactivity and inflammation in our allergic mouse 
model of asthma. Balb/c mice were divided into four groups: control (CON), CON + 
aerosolized AD (CON + AD), allergen sensitized and challenged (SEN), and SEN + 
aerosolized AD (SEN + AD). The animals were sensitized with ragweed (200 µg ip) on 
days 1 and 6, followed by 1% ragweed aerosol challenges from days 11 to 13. On day 14, 
the CON + AD and SEN + AD groups received a single AD aerosol challenge (6 mg/ml) 
for 2 min, followed by the collection of the aorta and plasma on day 15. Organ bath 
experiments showed concentration-dependent aortic relaxations to AD in the CON and 
CON+ AD groups, which were impaired in the SEN and SEN + AD groups. Real-time 
PCR data showed changes in aortic AD receptors (ARs), with the expression of A1ARs 
up-regulated, whereas the expression of A2ARs and endothelial nitric oxide synthase 
 19
genes were down-regulated, resulting in an impairment of vasorelaxation in the SEN and 
SEN + AD groups. The A1AR antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) 
reversed the impairment in vasorelaxation observed in the SEN and SEN + AD groups, 
whereas the A2BAR antagonist alloxazine inhibited vasorelaxation in all groups. Allergen 
challenge caused systemic inflammation in allergic mice, with AD aerosol further 
enhancing it as determined by the inflammatory cytokines profile in plasma. In 
conclusion, asthmatic mice showed altered vascular reactivity and systemic inflammation, 
with AD aerosol further exacerbating these effects.  
 
Introduction 
Asthma, a chronic disease affecting 10% of the population in North America, is 
characterized by perpetuation and amplification of inflammation in the airways and 
systemic circulation (Busse and Lemanske, 2001; Braman, 2006). Over the past two 
decades, adenosine has been increasingly implicated in the pathophysiology of asthma. 
Chronic cellular stress, inflammation and tissue damage observed in asthmatic airways 
are associated with increases in adenosine levels (Driver et al., 1993).  The inhalation of 
adenosine leads to bronchoconstriction in asthmatics as opposed to normal subjects who 
show no response to adenosine (Cushley et al., 1984). The elevation in lung adenosine 
levels observed in adenosine deaminase (ADA)-deficient mice lead to severe pulmonary 
inflammation, airway hyper-reactivity and airway remodeling (Chunn et al., 2001; 
Blackburn and Kellems, 2005), suggesting that a chronic elevation of adenosine levels 
can lead to the promotion of lung inflammation.  
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Several epidemiological studies have reported that people suffering from chronic 
respiratory diseases such as asthma are at an increased risk for developing cardiovascular 
complications (Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et al., 2004; 
Knoflach et al., 2005). Systemic inflammation in these patients is believed to be a 
consequence of airway inflammation (Jousilahti et al., 2002; Nadeem et al., 2003), which 
may be one of the reasons for altered cardiovascular parameters in these patients. Some 
recent studies have also reported enhanced systemic inflammation, myocardial ischemia-
reperfusion injury and neutrophil recruitment to the myocardium in animal models of 
allergic asthma (Hazarika et al., 2004, 2007). However, no study so far has attempted to 
establish a link between airway inflammation, vascular reactivity and systemic 
inflammation, especially in relation to adenosine. 
Adenosine has a well established role in the control of vascular tone, and its 
effects are exerted through the activation of the four different adenosine receptor (AR) 
subtypes: A1, A2A, A2B, and A3 (Tabrizchi and Bedi, 2001). A1 and A3 ARs have been 
shown be involved in vasoconstriction (Shepherd et al., 1996; Talukder et al., 2002b; 
Hansen et al., 2003; Tawfik et al., 2005) whereas A2A and A2B ARs cause vasorelaxation 
of aorta (Lewis et al., 1994; Grbovic and Radenkovic, 2003; Ansari et al., 2007b). 
However, the modulation of aortic ARs expression in response to allergen and adenosine 
aerosol challenge as an added insult in a murine model of asthma has not been previously 
studied.  
Allergen has been shown to cause the release of adenosine among other 
inflammatory mediators from allergic lung and activated leukocytes (Mann et al., 1986b; 
Mann et al., 1986a). Adenosine generated in allergic lungs may be involved in the release 
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of further chemotactic and inflammatory mediators in the lung and systemic circulation 
by acting on its receptors present on different cells including mast cells, eosinophils, 
neutrophils and other inflammatory cells (Driver et al., 1991; Fan and Jamal Mustafa, 
2006; Nadeem and Mustafa, 2006; Spicuzza et al., 2006). This has been confirmed by 
recent observations where experimentally induced temporary elevations in lung 
adenosine levels through the inhalation of adenosine (resulting from breakdown of 
adenosine 5'-monophosphate) have been shown to cause an increase in infiltration of 
eosinophils in patients with asthma (van den Berge et al., 2004). A recent study from our 
lab has also shown increased release of inflammatory cell markers in the lung and plasma 
after inhalation of adenosine aerosol in allergic mice (Fan and Mustafa, 2002). These 
studies thus suggest that adenosine inhalation amplifies allergen-induced airway 
inflammation in the lungs.  
Therefore, this study was undertaken to investigate the effects of inhaled 
adenosine on vascular reactivity and systemic inflammation using our murine model of 
asthma. Our data suggest that asthmatic mice have altered peripheral vascular reactivity 
and systemic inflammation, with inhaled adenosine further exacerbating these effects. 
 
Materials and Methods 
Animals: Balb/c mice, 8-10-wk-old males, were obtained from Harlan Sprague 
Dawley (Indianapolis, IN). The animals were maintained on a ragweed-free diet. All 
experimental animals used in this study were under a protocol approved by the 
Institutional Animal Care and Use Committee of West Virginia University. 
Animal sensitization: Sensitization was performed according to the protocol described 
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earlier from this laboratory (Fan and Mustafa, 2002; Fan et al., 2003; Oldenburg and 
Mustafa, 2005; Fan and Jamal Mustafa, 2006; Mustafa et al., 2007). This model of 
allergic asthma has been shown to develop airway inflammation and airway hyper-
reactivity to methacholine. The study comprised of four groups of animals: 1) Control 
(CON), 2) Control challenged with 6 mg/ml of adenosine aerosol for 2 min on day 14 
(CON + AD), 3) allergen sensitized and challenged (SEN), and 4) allergen sensitized and 
challenged further challenged with 6 mg/ml of adenosine aerosol for 2 min on day 14 
(SEN + AD). Mice were sensitized on days 1 and 6 with i.p. injections of ragweed 
allergen (Greer Laboratories, Lenoir, NC), 200 µg per dose with 200 µL Imject Alum 
(Pierce Laboratories, Rockford, IL). Non-sensitized control animals received only the 
Imject alum with the same volumes. Ten days after sensitization, the mice were placed in 
a Plexiglas chamber and challenged with 1% aerosolized ragweed or with 0.9% saline as 
a control, using an ultrasonic nebulizer (DeVilbiss Somerset, PA) for 20 min both in the 
morning and afternoon for three consecutive days. The aerosolization of allergen was 
performed at a flow rate of 2 mL/min, and the aerosol particles had a median 
aerodynamic diameter of less 4 µm (De Vilbiss).  
Acute elevations in lung adenosine levels were produced experimentally by 
adenosine inhalation (6 mg/ml for 2 min on day 14) to SEN+AD group to further enhance 
allergen-induced effects (the control for this group was CON+AD). This dose was chosen 
based on our previous studies in this model (Fan and Mustafa, 2002; Fan and Jamal 
Mustafa, 2006). Adenosine inhalation in this model has been shown to enhance allergen-
induced airway inflammation and airway hyper-reactivity to adenosine (or its analog 
NECA) (Fan and Mustafa, 2002; Fan et al., 2003; Fan and Jamal Mustafa, 2006). ADA- 
 23
deficient mice having sustained and chronic elevations in lung adenosine levels have also 
been shown to have similar features (Chunn et al., 2001). We chose 24-h post adenosine 
inhalation for our current studies based on an earlier study from our lab which showed 
maximum eosinophilic inflammation in airways after 24 h of adenosine inhalation (Fan 
and Jamal Mustafa, 2006), which is a hallmark of asthmatic inflammation. CON and SEN 
groups received only saline on day 14. Twenty-four hr after the last challenge, animals 
were sacrificed for collection of aorta and blood for further experiments. 
 
Preparation of isolated mouse aorta and isometric force measurement 
Mice were euthanized by anesthesia with pentabarbitol sodium (65 mg/kg ip) followed by 
thoracotomy and the removal of the aorta, which was then cut transversely into 3 to 4-mm 
rings. The rings were mounted vertically between two stainless steel wire hooks and then 
suspended in 10-ml organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit 
buffer (pH 7.4), containing (in mM) 118 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 
NaHCO3, 11 glucose, and 2.5 CaCl2, was maintained at 37°C with continuous bubbling 
of 95% O2-5% CO2. For the measurement of isometric force response, the aortic rings 
were equilibrated for 90 min with a resting force of 1 g and a change of the bathing 
solution at 15-min intervals. The resting force of 1 g has been used earlier in our 
laboratory (Tawfik et al., 2005; Ansari et al., 2007b). At the end of the equilibration 
period, the tissues were contracted with 50 mM KCl to check the contractility of 
individual aortic rings twice, which were washed out with Krebs-Henseleit buffer. The 
aortic rings were then constricted with phenylephrine (PE; 10–7 M) to obtain a steady 
contraction, and changes in tension were monitored continuously with a fixed-range 
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precision force transducer (TSD 125C; Biopac) connected to a differential amplifier (DA 
100B; Biopac). The data were recorded using the MP100 Biopac digital acquisition 
system and analyzed using Acknowledge 3.5.7 software (Biopac).  
 
Contraction/relaxation experiments 
After equilibration, the responsiveness and stability of individual rings were checked by 
successive administration of a submaximally effective concentration of PE (10–7 M). The 
integrity of the vascular endothelium was assessed pharmacologically by acetylcholine 
(10–7 M) to produce the relaxation of PE-precontracted rings. The aortic rings were then 
washed several times with Krebs-Henseleit solution and allowed to equilibrate for 30 min 
before the experimental protocol began.  
 
Experimental protocol 
The concentration-response curves (CRCs) for adenosine (10–11–10–4 M) were run in 
parallel in aortic rings from all the groups. In all cases, adenosine was added to yield the 
next higher concentration only when the response to the earlier dose reached a steady 
state. In experiments where the effects of an antagonist were measured, it was added 30 
min before the contraction of the tissue with PE and was present throughout the 
experiments.  
 
Real time PCR: A1, A2A, A2B, A3 AR and eNOS genes expression 
The aortic tissues from all experimental groups were processed for total RNA isolation 
using the TRIzol reagent from Life Technologies/Invitrogen, followed by DNase 
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treatment to eliminate potential genomic DNA contamination as described recently by our 
laboratory (Ansari et al., 2007b). This was followed by a conversion of 0.5 µg of total 
RNA into cDNA using a high-capacity cDNA archive kit (Applied Biosystems, Foster 
City, CA) in a total volume of 100 µl. Real-time PCR was then performed using an ABI 
PRISM 7300 detection system (Applied Biosystems) using Taqman Universal Mastermix 
(Applied Biosystems, Branchburg, NJ) according to the instructions of the manufacturer. 
The reaction volume (25 µl) consisted of (in µl) 12.5 2x Taqman Universal Mastermix, 1 
cDNA, and 1.25 20x 6-carboxy-fluorescein-labeled Taqman gene expression assay master 
mix solution. For the real-time PCR of the concerned genes [A1-, A2A-, A2B-, and A3AR 
and endothelial nitric oxide synthase (eNOS)], the Taqman inventoried assays-on-demand 
gene expression products (assay identifications for A3-, A2B-, A2A-, and A1AR and eNOS, 
respectively, are Mm00802076_m1, Mm00839292_m1, Mm00802075_m1, 
Mm01308023_m1, and Mm00435204_m1) were purchased from Applied Biosystems. 
18S ribosomal RNA was used as an endogenous control. The fold difference in the 
expression of target cDNA was determined using the comparative cycle threshold method 
as described earlier (Livak and Schmittgen, 2001). 
 
Assessment of systemic inflammation 
Mice were euthanized by pentobarbitone sodium (65 mg/mL, i.p.), followed by collection 
of blood by cardiac puncture in heparinized syringes. The blood collected from different 
groups was centrifuged at 800 g for 10 min at 4° C and the resulting plasma was used for 
cytokine and C-reactive protein (CRP) assays. 
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Multiplex cytokine assay: Multiplex cytokine assay of IL-1α, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-9, IL-10, IL-12 (p70), , IL-13, IL-15, IL-17, TNFα, IFNγ, GMCSF, MIP-
1α, MCP-1, KC, RANTES, IP-10, G-CSF in the plasma was measured by a commercial 
kit from Linco Research (St. Charles, Missouri) using the Luminex 200 system (Luminex 
Corp., Austin, Tx), which is a multianalyte bioassay detection system capable of 
performing up to 100 assays simultaneously in a single microtiter plate well. This system 
uses polystyrene microspheres internally dyed with red and infrared fluorophores that can 
be individually identified. The fluorescent microspheres were coated with capturing 
antibodies specific for different chemokines. The chemokine-captured beads after 
incubation with the sample were then mixed with phycoerythrin-conjugated detection 
antibodies to form immune complexes. Following incubation, washing and acquisition of 
fluorescence data, the concentration results were generated in graphical format using the 
standard curve generated for each cytokine. Results were expressed in pg/mL. 
C-reactive protein assay: C-reactive protein was measured in plasma with a mouse 
high-sensitive ELISA kit according to the instruction manual (Kamiya Biomedical 




Acetylcholine, adenosine and phenylephrine were dissolved in distilled water. 1,3-
dipropyl-8-cyclopentylxanthine (DPCPX) and 2, 4-dioxobenzo[g] pteridine (alloxazine) 
were dissolved in 100% DMSO as a 10 mM stock solution. The final concentration of 
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DMSO in the organ bath which had a total volume of 10 mL, had no effect by itself on 
the aortic rings (Ansari et al., 2007b). Unless stated otherwise, all chemicals were of the 
highest grade available and were purchased from Sigma Chemicals (St. Louis, MO). 
 
Statistical Analysis 
The data were expressed as mean± SEM. Comparisons among different groups were 
analyzed by ANOVA (analysis of variance) followed by Tukey’s multiple comparison 
test/Bonferroni’s selected pair test. Comparison between two groups was assessed by 
unpaired t-test. A p value of less than 0.05 was considered as the level of significance for 




Systemic inflammation in control, allergic and adenosine aerosolized allergic mice 
Table 3.1 shows the multiplex cytokine profile in all the groups. Allergen challenge 
significantly increased plasma levels of inflammatory cytokines IL-5, IL-6, IL-13, and 
MCP-1 in sensitized (SEN) compared with control (CON) mice. Allergen-sensitized and 
challenged mice exposed to adenosine aerosol (SEN + AD) had the highest level of the 
pro-inflammatory cytokines including IL-1β, IL-5, IL-13, MCP-1, MIP-1α and TNF-α 
compared to other groups. Other cytokines in the panel were either undetectable or not 
different among the groups (data not shown). In addition, the cytokine profile was also 
studied in the CON + AD group. Cytokine levels were not different between this group of 
animals aerosolized with adenosine compared with the CON group, suggesting that 
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aerosolized adenosine in the absence of allergic inflammation had no effect on the 
inflammatory cytokine profile. CRP was also measured as an important systemic 
inflammatory marker. Plasma CRP levels significantly increased in the SEN compared 
with the CON group, with a further increase in the SEN + AD compared with the SEN 
group. Again, there was no difference between the CON and CON + AD groups in CRP 
levels. These data show that sensitized mice challenged with allergen have systemic 
inflammation and that aerosolized adenosine further enhances the inflammation in these 
mice. Earlier studies from our laboratory have also shown no difference in the lung 
inflammation of control mice aerosolized with adenosine (Fan and Mustafa, 2002; Fan 
and Jamal Mustafa, 2006). 
 
Vascular reactivity in control, allergic and allergic + adenosine groups 
The aortic relaxation/contraction responses to adenosine were studied in each of the 
following four groups: CON, CON + AD, SEN, and SEN + AD. Organ bath data showed 
a concentration-dependent relaxation response to adenosine in the CON aorta (Fig. 3.1). 
The maximum relaxation produced by adenosine (10–4 M) was 21% and 25% in the CON 
and CON + AD groups, respectively. There was no difference in the vasorelaxation 
between the CON and CON + AD groups. Adenosine-induced aortic relaxations were 
impaired in the SEN aorta with a maximum relaxation of 7%. The impairment of 
vasorelaxation response to adenosine observed in the SEN group was further aggravated 
in the SEN + AD aorta. Adenosine failed to elicit any relaxation response in the SEN + 
AD group; however, it produced a contractile response (–5%) at higher doses. These data 
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show that allergen sensitization and challenge altered the vascular reactivity, with 
adenosine aerosol further exacerbating it in allergic mice.  
 
Endothelial function and eNOS expression in control, allergic and allergic + 
adenosine groups 
The SEN and SEN + AD groups had significantly lower (~50% relaxation) endothelial 
response to acetylcholine (Fig 3.2A) compared with that of the respective controls (~75% 
relaxation). Real-time PCR data also showed that the expression of eNOS in the aorta was 
significantly decreased in the SEN and SEN + AD groups compared with the Con group 
(Fig 3.2B). These data show that allergen challenge probably led to dysfunctional 
endothelium in the SEN and SEN + AD groups.  
With the aerosolization of adenosine, it is difficult to assess the exact amount of 
adenosine reaching the lungs. However, the dose we have chosen is based on previous 
work from our laboratory (Fan and Mustafa, 2002; Fan et al., 2003; Fan and Jamal 
Mustafa, 2006). This dose of adenosine (6 mg/ml) has no systemic effects, which has 
been shown by the lack of any systemic inflammation, improvement in vascular 
reactivity, and endothelial response in the CON + AD compared with the CON group. We 
also know that the half-life for adenosine is less than a minute. In fact, this was the reason 
why adenosine was chosen and not an adenosine analog. Most of the systemic effects of 
this dose would be gone within minutes. Therefore, it is unlikely that the effects of 
adenosine in this study are due to any hemodynamic changes in these animals.  
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Adenosine receptors gene expression in control, allergic and allergic + adenosine 
groups 
To gain further insight into the pattern of the expression of ARs and their involvement in 
the impairment of vasorelaxation observed in the SEN and SEN + AD groups, we first 
measured the aortic gene expression of all ARs before conducting organ bath 
experiments. Real-time PCR data showed that A1 (Fig 3.3A), A2A (Fig 3.3B) and A2BAR 
(Fig 3.3C) expression was decreased in the SEN compared with the CON group, whereas 
A3AR expression remained unaffected (data not shown). The expression of A1AR 
increased significantly in the SEN + AD compared with the SEN group, whereas A2A- 
and A2BARs decreased further; however, only the decrease in A2BAR expression reached 
statistical significance. These data show that an alteration in AR expression is responsible 
for the impairment of vasorelaxation observed in the SEN and SEN + AD groups.  
 
Effect of specific A1 AR (DPCPX) and A2B AR (alloxazine) antagonists on vascular 
reactivity in control, allergic and allergic + adenosine groups 
Based on real-time PCR data, we used the A1AR antagonist to reverse the impairment 
observed in the SEN and SEN + AD groups since A1AR activation has been shown to 
cause vasoconstriction in earlier studies from our laboratory (Tawfik et al., 2005). 
Treatment of the aorta with the A1AR antagonist DPCPX (10–5 M) before concentration-
response with adenosine resulted in a reversal of impaired vasorelaxation in the SEN and 
SEN + AD groups (Fig 3.4). DPCPX shifted the CRC to adenosine toward the left in the 
SEN and SEN + AD groups, with the vasorelaxation observed in these groups being 
similar to the CON group (Fig 3.1). A concentration-dependent relaxation was seen in 
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CON animals (CON and CON + AD), which was not affected by DPCPX except at the 
highest concentration of adenosine that was significant (data not shown).  
We expected the inhibition of vasorelaxation by the blocking of A2BAR since it is 
considered to be involved in the relaxation of the aorta (Grbovic and Radenkovic, 2003; 
Ansari et al., 2007b). The pretreatment of the aorta with the A2BAR antagonist alloxazine 
(10–4 M) before CRC with adenosine resulted in the inhibition of vasorelaxation observed 
in the CON and CON + AD aorta. Alloxazine shifted the CRC to adenosine toward the 
right, indicating a contraction in the CON and CON + AD aorta (Fig 3.5A). Impaired 
vasorelaxation observed in the SEN and SEN + AD groups was also affected by prior 
treatment of the aorta with alloxazine (Fig 3.5B), with a further rightward shift of their 
respective CRCs. These data suggest that A1- and A2BARs have a significant role in the 
impairment of vascular reactivity observed in the SEN and SEN + AD groups. DPCPX 
and alloxazine are selective inhibitors of A1- and A2BAR, respectively, and have been 
used by others and our laboratory in earlier studies (Rose Meyer et al., 2003; Tawfik et 











Table 3.1: Systemic inflammation as assessed by levels of inflammatory cytokines in 
plasma of control (CON), adenosine aerosolized control (CON+AD), allergic (SEN) 
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Figure 3.1 Concentration-response curves for adenosine mediated relaxation/contraction 
in control (CON), adenosine aerosolized control (CON+AD), allergic (SEN) and 
adenosine aerosolized allergic (SEN+AD) mice. Values are expressed as mean ± SEM 
(n=8). On the ordinate, positive and negative values indicate relaxation and contraction, 
respectively. *P<0.05 as compared to CON/CON+AD; # P<0.05 as compared to SEN. 
 
 
























Figure 3.2 Endothelial responses to ACh in control (CON), adenosine aerosolized 
control (CON+AD), allergic (SEN) and adenosine aerosolized allergic (SEN+AD) mice. 
(A) Effect of acetylcholine (10-7 M) on phenylephrine (PE) precontracted aorta (n=8); (B) 
Expression of eNOS by real time PCR (n=4). For gene expression by comparative CT 
method using real time PCR, the CON group was used as the calibrator against which all 
other groups were compared. Values are expressed as mean ± SEM. *P<0.05 as compared 
to CON/CON+AD.  
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Figure 3.3 Expression of (A) A1, (B) A2A, and (C) A2B adenosine receptors by real time 
PCR in mice aorta of control (CON), allergic (SEN) and adenosine aerosolized allergic 
(SEN+AD) mice. For gene expression by comparative CT method using real time PCR, 
the CON group was used as the calibrator against which all other groups were compared. 
Values are expressed as mean ± SEM (n=4). *P<0.05 as compared to CON; #P<0.05 as 
compared to SEN. 






























































Figure 3.4 Effect of a specific A1 AR antagonist, DPCPX (10-5 M) on adenosine-
mediated relaxation/contraction in aorta of allergic (SEN) and adenosine aerosolized 
allergic (SEN+AD) mice. Values are expressed as mean ± SEM (n=8). On Y-axis, 
positive and negative values indicate relaxation and contraction respectively. *P<0.05 as 
compared to SEN/SEN+AD.  
 





























Figure 3.5 Effect of A2B AR antagonist, Alloxazine (10-4 M) on adenosine-mediated 
relaxation/contraction in aorta of (A) control mice (CON); and (B) allergic (SEN) and 
adenosine aerosolized allergic (SEN+AD) mice. Values are expressed as mean ± SEM 
(n=4-8). On Y-axis, positive and negative values indicate relaxation and contraction 
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The principal finding of the present study is that allergic mice had impaired 
vasorelaxation to adenosine and systemic inflammation, both of which were further 
aggravated after acute adenosine aerosol challenge in these mice. The AR expression 
profile was also altered in allergic mice and those aerosolized with adenosine after 
allergen challenge, which resulted in an impairment of vasorelaxation in these mice. 
Endothelium was found to be dysfunctional in both of these groups, since they had a 
decrease in aortic eNOS expression and endothelial relaxation to acetylcholine. The 
A1AR antagonist DPCPX attenuated the impairment in vasorelaxation observed in 
allergic mice and those subjected to adenosine aerosol after allergen challenge, whereas 
the A2BAR antagonist alloxazine impaired the vasorelaxation further in these groups, 
supporting a role for A2BAR in aortic relaxation.  
Airway inflammation is associated with chronic elevations in lung adenosine 
levels that may be due to the release of adenosine among other inflammatory mediators 
from sensitized lung and activated leukocytes (Mann et al., 1986b; Mann et al., 1986a; 
Driver et al., 1993). This is also experimentally supported by chronically increasing lung 
adenosine levels by knocking out ADA, an enzyme responsible for adenosine breakdown 
or temporarily by the inhalation of adenosine aerosol, as in this study. Mice deficient in 
the ADA enzyme develop severe pulmonary inflammation, airway hyperreactivity, and 
airway remodeling in association with the elevated levels of adenosine in the lungs 
(Chunn et al., 2001; Blackburn and Kellems, 2005). Adenosine inhalation to the allergic 
lungs has also been shown to increase further airway responsiveness and inflammatory 
mediators (Driver et al., 1991; Fan and Mustafa, 2002; van den Berge et al., 2004; Fan 
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and Jamal Mustafa, 2006), suggesting an important role for adenosine in the amplification 
of lung inflammation.  
Systemic inflammation has also been reported earlier in humans with asthma and 
animal models of asthma (Jousilahti et al., 2002; Hazarika et al., 2004). Hazarika et al 
(Hazarika et al., 2007) recently showed an increase in neutrophils and eosinophils in the 
bronchoalveolar lavage and blood in a murine model of asthma. Systemic inflammatory 
markers have also been shown to be elevated in patients with asthma and in the allergic 
mouse model of asthma after the adenosine aerosol challenge performed earlier by our 
laboratory (Driver et al., 1991; Fan and Jamal Mustafa, 2006). We further extended these 
observations in the present study to investigate the cytokine profile in systemic 
circulation in our murine model of asthma. We found that allergic mice exposed to acute 
adenosine aerosol had increased systemic inflammation since several pro-inflammatory 
cytokines levels (IL-1β, IL-5, IL-13, MCP-1, MIP-1α and TNF-α) were found to be the 
highest in this group. A recent report from this laboratory using this model of asthma has 
also shown increased activities of eosinophilic peroxidase, myeloperoxidase and β-
hexosaminidase not only in the lung but also in the systemic circulation of allergic mice 
exposed to adenosine aerosol (Fan and Jamal Mustafa, 2006). Adenosine aerosol in 
humans with asthma has also been shown to cause increased release of neutrophil 
chemotactic factor in serum (Driver et al., 1991). These studies suggest that adenosine 
enhances the release of systemic inflammatory mediators from sensitized inflammatory 
cells. Our murine model of asthma, therefore, was appropriate to study the inflammatory 
effects of adenosine in combination with allergen on vascular reactivity. 
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Asthma has been associated with an increased incidence of cardiovascular 
disorders (Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et al., 2004; 
Knoflach et al., 2005); however, there is little information regarding the role of asthmatic 
inflammation in the development of cardiovascular disease, especially in relation to the 
vascular effects of adenosine. In the present study, adenosine produced a concentration-
dependent vasorelaxation in control mice, which was impaired in allergic mice. Vascular 
reactivity to adenosine was further altered in aorta of allergic mice that had received 
aerosolized adenosine. These data implicated a role for ARs in impairment of the 
vasorelaxation response in allergic mice and those challenged with adenosine aerosol 
after allergen. We have found that allergic animals subjected to theophylline inhalation 
before adenosine aerosol challenge had improved aortic vasorelaxation to the non-
selective adenosine analog 5'-N-ethylcarboxamidoadenosine (NECA; unpublished data). 
This further supports a role for adenosine in impaired vasorelaxation. 
As the direct effects of adenosine on hemodynamic parameters (blood pressure, 
oxygen saturations, and heart rate) were not assessed, it is possible that there could be 
adenosine-mediated effects on vasculature independent of inflammation in the allergic 
group (SEN + AD). The exact cause of why adenosine inhalation blunted aortic 
vasorelaxation to adenosine in sensitized and challenged mice, but not in control mice, is 
unclear. However, because the CON + AD group did not show a change in inflammatory 
markers and vasorelaxation to adenosine, it is likely that changes observed in the 
vasculature were due to allergen and adenosine in sensitized mice. Further studies are 
needed to completely assess the effects of adenosine on hemodynamic parameters in this 
model of asthma. 
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To gain further insight into the AR responsible for the alteration in vascular 
reactivity, changes in ARs expression in allergen and adenosine-aerosolized allergic mice 
were measured. Real time PCR data showed a down-regulation of A1, A2A and A2B ARs 
in allergen-sensitized and challenged mice, the net result possibly being the impaired 
vasorelaxation observed in this group since it is known that A2A AR and A2B AR are 
involved in vasorelaxation (Grbovic and Radenkovic, 2003; Ansari et al., 2007b). A2A 
and A2B ARs expression decreased further and the A1 AR expression increased in allergic 
mice exposed to adenosine aerosol compared with allergic mice, leading to aortic 
contraction in this group. This effect could be due to the combined net result of an 
increase in the A1 AR and further decrease in the expression of A2 ARs since the former 
is involved in vasoconstriction and latter in vasorelaxation, as shown in earlier studies 
from others and our laboratory (Lewis et al., 1994; Tawfik et al., 2005; Ansari et al., 
2007b). 
Real-time PCR studies of ARs prompted us to look further into the roles of A1 AR 
and A2B AR on vascular responses. The A2B AR antagonist alloxazine blocked the 
vasorelaxation in controls and caused a further impairment in allergic mice and those 
exposed to adenosine aerosol after allergen challenge, suggesting that adenosine-
mediated vasorelaxation could mainly be via the A2B AR. The A1 AR antagonist DPCPX 
reversed the impaired vasorelaxation in allergic mice and those exposed to adenosine 
aerosol after allergen challenge, suggesting that the A1 AR has an important role in 
vasoconstriction, especially when the vasorelaxant A2B AR is downregulated. In an 
unpublished observation from our lab, pretreatment of aorta with the selective A2A 
antagonist, SCH 58261, showed a decrease in NECA-induced aortic relaxation in control 
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mice. However, SCH 58261 pretreatment did not have any significant effect on altered 
aortic relaxation to NECA observed in SEN and SEN + AD groups, suggesting a limited 
role in vascular reactivity for the A2A AR in this particular experimental model.  In 
conclusion, the data further support the involvement of A1 AR in contraction and A2B AR 
in relaxation of mice aorta in our model of allergic asthma.  
The endothelium serves as an important regulator of vascular function and 
homeostasis by releasing mediators such as nitric oxide and prostaglandins (Mombouli 
and Vanhoutte, 1999); however, its role in relation to allergen exposure and adenosine 
challenge has not been explored. Allergen exposure probably contributed to the 
impairment in endothelial responses observed in allergic and adenosine aerosolized 
allergic mice since eNOS expression and vasorelaxation to acetylcholine was decreased 
equally in both of these groups. The exact cause of this dysfunction is not known but it 
could be possibly due to an increase in systemic inflammatory cytokines as they are 
reported to suppress eNOS and nitric oxide production (Cardaropoli et al., 2003; Li et al., 
2004). 
Endothelial dysfunction has been reported earlier after exposure to particulate 
matter in aorta of mice (Cozzi et al., 2006). Nurkiewicz et al (Nurkiewicz et al., 2004) 
have also shown impairment of endothelium-dependent arteriolar dilation in rat 
spinotrapezius muscle upon inhalation of particulate matter. Endothelial dysfunction 
caused by allergen exposure could be somewhat similar to that of particulate matter 
exposure in many ways. First, allergen particle size is in the same range as that of 
particulate matter. Second, particulate matter is known to cause lung inflammation, which 
spills over in systemic circulation, leading to endothelial dysfunction and other 
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cardiovascular complications (Nurkiewicz et al., 2006; Bai et al., 2007). It is also 
reported to be associated with pulmonary as well as cardiovascular disorders (Schwarze 
et al., 2006).  
The fact that endothelial responses to acetylcholine and eNOS expression were 
almost equal in allergic mice and those exposed to adenosine aerosol after allergen 
challenge, whereas vasorelaxation responses to adenosine were different between these 
groups, could be due to two reasons. First, it could be due to the further increase in 
several pro-inflammatory cytokines found in allergic mice exposed to adenosine aerosol 
as some of these cytokines are reported to directly alter vascular function (Tousoulis et 
al., 2006). Second, it could be due to the increased A1AR and decreased A2B AR 
expression favoring aortic contraction in allergic mice exposed to adenosine aerosol. 
Further studies are required to delineate the role of each AR in alteration of vascular 
responses using specific AR knock-out mice.  
In conclusion, our findings provide evidence for the first time that there are 
alterations in systemic parameters (inflammation, lower endothelial response and 
impaired vasorelaxation to adenosine) as a result of allergen exposure and adenosine 
aerosol challenge in sensitized mice. Therefore, therapeutic strategies designed to 
attenuate lung inflammation should also focus on the prevention of systemic 
inflammation and harmful systemic side effects. This strategy may be beneficial in 











Adenosine mediates vascular responses through its 4 receptor subtypes: A1, A2A, 
A2B and A3. In the murine aorta, the A2B receptor is believed to contribute to 
vasorelaxation while the role of the A2A receptors is not well documented. The current 
study was undertaken to investigate the role of A2A receptors on aortic tone using A2A 
adenosine receptor knock-out (A2AKO) and corresponding wild-type (A2AWT) mice for 
experiments along with suitable pharmacological tools. Experiments included organ bath 
studies and real time RT-PCR for adenosine receptor (AR) gene expression studies. 
Isolated aortic rings prepared from A2AWT and A2AKO mice were precontracted with 
phenylephrine (10-7M) and concentration-response curves for adenosine analogs and 
selective agonists/antagonists were obtained. NECA (non-selective adenosine analog; 
EC50 = 6.78µM) and CGS 21680 (A2AAR selective agonist; EC50 = 0.013µM) produced 
concentration-dependent relaxation (25% and 28% relaxation with NECA at 10-5M and 
CGS 21860 at 10-5M, respectively) in A2AWT aorta. In A2AKO aorta, NECA (EC50 = 
0.075µM) induced concentration-dependent contraction (47% at 10-6M; p<0.05 compared 
to A2AWT) while CGS 21860 produced no response. SCH 58261 (10-6 M; A2AAR 
selective antagonist) abolished vasorelaxation in A2AWT (p<0.05) while no change was 
observed in A2AKO. When DPCPX (10-5 M; A1 selective antagonist) was used, greater 
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vasorelaxation was observed in A2AWT (50% vs. 25% in controls; p<0.05) while A2AKO 
showed less contraction (5% vs. 47% in controls; p<0.05). Aortic endothelial function, 
determined by the response to acetylcholine, was significantly greater in WT compared to 
KO (66% in WT vs. 51% in KO; p<0.05). In conclusion, A2AAR KO mice had 
significantly lower aortic relaxation and endothelial function, suggesting that the A2AAR 
plays an important role in vasorelaxation, probably with the endothelium playing a role. 
 
Introduction 
Adenosine is a ubiquitous endogenous nucleoside that has several physiological 
effects which are mediated through the four adenosine receptor (AR) subtypes, i.e., A1, 
A2A, A2B and A3. Adenosine is known to modulate cardiac effects (Shryock and 
Belardinelli, 1997) and vascular responses. A1 receptors are involved in lowering the 
heart rate (Evans et al., 1982; Belardinelli et al., 1989) and have a negative role in 
regulating blood pressure (Brown et al., 2006). All four receptors are involved in the 
regulation of vascular responses (Tabrizchi and Bedi, 2001). The vascular effects of 
adenosine differ according to the receptor subtype activated, the type of vascular bed 
involved and the species. 
A1 and A3 ARs have been shown to be involved in vasoconstriction (Shepherd et 
al., 1996; Talukder et al., 2002b; Hansen et al., 2003; Tawfik et al., 2005) whereas A2A 
and A2B ARs cause vasorelaxation (Lewis et al., 1994; Grbovic and Radenkovic, 2003; 
Ansari et al., 2007b). The A2AAR was found to play a major role in the mediation of 
coronary vasodilation caused by adenosine and adenosine agonists (Belardinelli et al., 
1998). In rat kidneys, the vasoconstrictor response is mediated via the activation of A1 
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receptors (Rossi et al., 1988) and both A2A and A2B receptors are present in renal 
microvasculature, contributing differentially to vasodilation (Tang et al., 1999). In the 
pulmonary circulation, findings suggest that adenosine induced relaxation is mediated via 
the A2B receptor via a nitric oxide independent mechanism (Haynes et al., 1995). It has 
been found that in mice, adenosine-induced aortic relaxation is predominantly mediated 
via A2B adenosine receptor activation (Talukder et al., 2002a) and the response is 
endothelium-mediated through nitric oxide release (Ansari et al., 2007b). In the guinea 
pig, the A2A receptor is involved in coronary vessel relaxation whereas the A2B receptor is 
present predominately in the aorta (Martin et al., 1993; Shryock et al., 1998). Similarly, 
the vascular effect of adenosine in aorta and coronary vessels of rat has been reported to 
be mediated by both A2A and A2B receptors (Lewis et al., 1994; Lewis and Hourani, 
1997).  
The A2A receptor, though present in mouse aorta, has not been extensively studied 
in aortic relaxation and its role in the modulation of aortic vascular responses is unclear.  
This study was, therefore, undertaken to determine vascular responses mediated via the 
A2A receptor. Both pharmacological tools and genetically modified mice in which the A2A 
receptor was knocked out were used in the experiments. Isolated in vitro preparations of 
aortic rings from A2AWT and KO mice were used to study the effects of A2A adenosine 
receptors on vascular smooth muscle tone using adenosine analogs (NECA), selective 
agonists (CGS 21860-A2A selective agonist; BAY 60-6583-A2B selective agonist) and 
antagonists (SCH5830-A2A selective antagonist; DPCPX-A1 selective antagonist and 
alloxazine-A2B selective antagonist). Gene expression of the four adenosine receptor 
subtypes was also determined using aorta from both A2AWT and KO mice in real time 
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RT-PCR experiments. We hypothesized that adenosine A2A receptors contributed to 
adenosine-mediated vascular relaxation, in part through an endothelium-dependent 
pathway. Our results indicate that the A2A receptor does contribute to aortic relaxation, 
more than previously thought. 
 
Materials and Methods 
Mice 
A2A KO and wild-type (WT) mice were obtained from the Institute of Experimental 
Medicine (C. Ledent, Universite Libre de Bruxelles, Brussels, Belgium). To homogenize 
the genetic background of the mice, the first-generation heterozygotes were bred for 14 
generations on a CD1 (Charles River) outbred background, with selection for the mutant 
A2A gene at each generation by PCR. Fourteenth-generation heterozygotes were bred 
together to generate the A2A KO and WT. Twelve to fourteen week old males and females 
were used for experiments. All experimental animals used in this study were under a 
protocol approved by the Institutional Animal Care and Use Committee of West Virginia 
University. 
 
Preparation of isolated mouse aorta and isometric force measurement 
Mice were sacrificed by anesthesia with pentabarbitol sodium (65 mg/kg, i.p.) followed 
by thoracotomy and removal of aorta that was then cut transversely into 3-4 mm rings. 
The rings were mounted vertically between two stainless steel wire hooks and then 
suspended in 10 mL organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit 
buffer (pH 7.4) containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM 
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KH2PO4, 25 mM NaHCO3, 11 mM glucose and 2.5 mM CaCl2 was maintained at 37°C 
with continuous bubbling of 95% O2 and 5% CO2. For measurement of isometric force 
response, aortic rings were equilibrated for 90 min with a resting force of 1g (Tawfik et 
al., 2005; Ansari et al., 2007b) and change of the bathing solution at 15 min interval. At 
the end of equilibration period, tissues were contracted with 50 mM KCl to check the 
contractility of individual aortic rings twice which were washed out with Krebs-Henseleit 
buffer. Aortic rings were then constricted with phenylephrine (PE, 10-7M) to obtain a 
steady contraction and changes in tension were monitored continuously with fixed range 
precision force transducer (TSD, 125 C, BIOPAC system) connected to the differential 
amplifier (DA 100B, BIOPAC system). The data were recorded using MP100, BIOPAC 




After equilibration, the responsiveness and stability of individual rings were checked by 
successive administration of submaximally effective concentration of PE (10-7 M). The 
integrity of the vascular endothelium was assessed pharmacologically by acetylcholine 
(10-7 M) to produce relaxation of PE pre-contracted rings. Aortic rings were then washed 
several times with Krebs-Henseleit solution, and allowed to equilibrate for 30 min before 
the experimental protocol began. In experiments where the involvement of endothelium 
was investigated, endothelium was removed mechanically prior to mounting in the bath, 





The concentration-response curves (CRCs) for NECA (10-11 -10-5 M), CGS 21860 (10-11 -
10-5 M) and BAY 60-6583 (10-11 -10-5 M) were run in parallel in aortic rings from A2AWT 
and KO mice. In all cases, the drug was added to yield the next higher concentration only 
when the response to the earlier dose reached a steady state. In experiments where the 
effects of an antagonist were measured, it was added 30 min before contraction of the 
tissue with PE, and was present throughout the experiments. Contraction/relaxation 
responses were expressed as a percentage increase/decrease in the contraction with 
respect to PE (alone) in response to each concentration of agonist used. 
 
Real time PCR: A1, A2A, A2B, and A3 AR genes expression 
The aortic tissues were processed for total RNA isolation using the TRIzol reagent from 
Life Technologies/Invitrogen followed by DNase treatment to eliminate potential 
genomic DNA contamination as described recently by us (Ansari et al., 2007b). This was 
followed by conversion of 0.5 μg of total RNA into cDNA using High Capacity cDNA 
archive kit (Applied Biosystems, Foster City, CA) in a total volume of 100 ul. Real-time 
PCR was then performed using an ABI PRISM 7300 Detection System (Applied 
Biosystems) using Taqman Universal Mastermix (Applied Biosystems, Branchburg, New 
Jersey) according to the instructions of the manufacturer. The reaction volume (25 μL) 
consisted of 12.5 μL of 2X Taqman Universal Mastermix, 1 μL of cDNA, and 1.25 μL of 
20X FAM-labeled Taqman gene expression assay master mix solution. For the real-time 
PCR of the concerned genes (A1AR, A2AAR, A2BAR and A3AR), the Taqman inventoried 
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assays-on-demand gene expression products (Assay IDs for A3AR, A2BAR, A2AAR, and 
A1AR respectively are Mm00802076_m1; Mm00839292_m1; Mm00802075_m1 and 
Mm01308023_m1) were purchased from Applied Biosystems (Foster City, CA). 18S 
rRNA (Ribosomal RNA) was used as an endogenous control. The fold difference in 
expression of target cDNA was determined using the comparative CT method as 
described earlier (Livak and Schmittgen, 2001). 
 
Drugs used 
Acetylcholine, adenosine and phenylephrine were dissolved in distilled water. 1,3-
Dipropyl-8-cyclopentylxanthine (DPCPX), 2-p-(2-carboxyethyl)phenethylamino-5' N-
ethylcarboxamido adenosine hydrochloride (CGS 21680), SCH 58261, BAY 60–6583 
and 2, 4-dioxobenzo[g]pteridine (alloxazine) were dissolved in 100% DMSO as a 10 mM 
stock solution. The final concentration of DMSO in organ bath (10 mL) had no effect by 
itself on the aortic rings (Ansari et al., 2007b). Unless stated otherwise, all chemicals 




The data were expressed as mean±SEM. Comparisons among different groups were 
analyzed by ANOVA (analysis of variance) followed by Tukey’s multiple comparison 
test/Bonferroni’s selected pair test. Comparison between two groups was assessed by 
unpaired t-test. A p value of less than 0.05 was considered as the level of significance for 
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all statistical tests. All the statistical analyses were performed using Graph Pad Prism 
statistical package. 
Results 
Response to NECA, CGS-21680 and BAY 60–6583 
The aortic relaxation/contraction responses to NECA, CGS-21680 and BAY 60-6583 
were studied in A2AWT and KO mice. Organ bath data showed a concentration-
dependent contraction response to NECA, a non-selective adenosine analog, in A2AKO 
aorta while a biphasic concentration response was observed in A2AWT aorta (Fig. 4.1). 
The maximum contraction produced by NECA (10-6 M) was 45% in KO and maximum 
relaxation in WT was 25% (10-5 M). CGS-21680, a selective A2A agonist, produced a 
concentration-dependent relaxation response in A2AWT aorta (30% at 10-5 M; Fig 4.2) 
while BAY 60-6583, a selective A2B agonist,  produced relaxation in both A2AWT and 
KO aorta (38% and 33% respectively at 10-5 M; Fig 4.3). These data show that A2AWT 
and KO mice had different adenosine-mediated vascular-responses, with the A2A and A2B 
receptors eliciting relaxation. 
 
Endothelial function in A2AWT and KO aorta 
A2AKO mice had significantly lower (~50% relaxation) aortic endothelial response to 
acetylcholine (Fig. 4.4 A) compared to the respective WT (~75% relaxation in controls) 
group.   
To determine the contribution of the endothelium to A2A mediated relaxation, we 
next evaluated the CGS 21860 concentration-response relationship in A2A WT aortic 
tissue in which the endothelium had been scraped off (-E), as described in the method 
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section.  Removal of the endothelium abolished CGS-21860 induced relaxation (Fig 4.4 
B), suggesting the A2A receptor-mediated relaxation involved an endothelium dependent 
mechanism. 
 
Adenosine receptors gene expression in A2AWT and KO mice 
To gain further insight into the pattern of adenosine receptors (AR) expression and their 
involvement in vasorelaxation observed in A2AWT and KO groups, we measured aortic 
gene expression of all four ARs. Real time PCR data showed that there was no difference 
in receptor expression between A2AWT and KO mice (Fig 4.5). These data suggest that 
the absence of the A2A receptor contributed to lower NECA-mediated relaxation in 
A2AKO mice. 
 
Effect of specific A1 AR (DPCPX), A2A AR (SCH 58261) and A2B AR (alloxazine) 
antagonists on vascular reactivity in A2A WT and KO mice 
Treatment of aorta with  the A1 AR antagonist, DPCPX (10-5 M; Fig. 4.6) prior to 
concentration response curve (CRC) with NECA resulted in concentration-dependent 
vasorelaxation in A2AWT aorta with maximum relaxation being 50% at 10-5M NECA. In 
A2AKO aorta, DPCPX lowered the magnitude of contraction response, however no 
relaxation response was observed. The selective A2A antagonist, SCH 58261 (10-6 M) 
abolished NECA- and CGS 21860-mediated relaxation, respectively, in A2AWT aorta 
(Fig 4.7 A and Fig 4.7 B) while it had no effect in A2AKO tissue (data not shown). 
We expected inhibition of vasorelaxation by blocking of A2B AR as it is 
considered to be involved in relaxation of aorta from mice (Grbovic and Radenkovic, 
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2003; Ansari et al., 2007b). Pre-treatment of aorta with the A2B AR antagonist alloxazine 
(10-5 M) prior to NECA concentration-response resulted in inhibition of vasorelaxation 





















Figure 4.1 Concentration-response curves for NECA-mediated relaxation/contraction in 
A2AWT and A2AKO mice. Values are expressed as mean ± SEM (n=8). On the ordinate, 











































Figure 4.2 Concentration-response curves for CGS 21860-mediated 
relaxation/contraction in A2AWT and A2AKO mice. Values are expressed as mean ± SEM 













































Figure 4.3 Concentration-response curves for BAY60-6583-mediated 
relaxation/contraction in A2AWT and A2AKO mice. Values are expressed as mean ± SEM 






































Figure 4.4 A) Endothelial response in A2AWT (~70%) and A2AKO (~50%) mice to 
acetylcholine. Values are expressed as mean ± SEM (n=8). *P<0.05 B) CGS 21860 
response in A2AWT endothelium denuded (-E) aorta (n=4-8) 
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Figure 4.5 Adenosine receptor gene expression in A2AWT and A2AKO aorta. Values are 
expressed as mean ± SEM (n=8).  There was no difference in the receptor expression 






































Figure 4.6 Effect of the selective A1 antagonist DPCPX on NECA-mediated 
relaxation/contraction in A2AWT and A2AKO mice. Values are expressed as mean ± SEM 
(n=8). On the ordinate, positive and negative values indicate relaxation and contraction, 
respectively. Use of DPCPX produced significantly more relaxation in A2AWT aorta 
(*P<0.05) compared to the response in untreated WT tissues. In the A2AKO tissues, 











































Figure 4.7 Effect of the selective A2A antagonist SCH 58261 on (A) NECA- and (B) 
CGS 21860-mediated relaxation/contraction in A2AWT aorta Values are expressed as 
mean ± SEM (n=8). On the ordinate, positive and negative values indicate relaxation and 
contraction, respectively. *p<0.05 
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Figure 4.8 Effect of the selective A2B antagonist alloxazine (10-5 M) on NECA-mediated 
relaxation/contraction in A2AWT mice. Values are expressed as mean ± SEM (n=8). On 
the ordinate, positive and negative values indicate relaxation and contraction, 
respectively. Use of alloxazine produced significantly less relaxation in A2AWT aorta 







































Figure 4.9 Effect of the selective A2B antagonist alloxazine (10-5 M) on NECA-mediated 
relaxation/contraction in A2AKO mice. Values are expressed as mean ± SEM (n=8). On 
the ordinate, positive and negative values indicate relaxation and contraction, 
respectively. Use of alloxazine produced more contraction in A2AKO aorta compared to 






































 The primary objective of this study was to determine whether A2A adenosine 
receptors play any role in aortic vasorelaxation in mice. Our principal finding is that 
A2AKO mice had lowere aortic vasorelaxation and endothelium relaxation response 
compared to WT counterparts. The data indicates a role for endothelium-dependent A2A 
receptor mediated vasorelaxation in mouse aorta with the A2B receptor also contributing 
to aortic vascular relaxation. 
 The A2 receptors are involved in adenosine-dependent vasorelaxation in almost 
all vascular beds studied, with the A2A and A2B contributing to the responses (Mustafa 
and Askar, 1985; Ramgopal MV et al., 1988; Abebe et al., 1994; Mustafa and Abebe, 
1996; Ralevic and Burnstock, 1998). In mouse aorta, high affinity A2A receptors are 
present but thier role in aortic vasorelaxation has not been established, while low-affinity 
A2B receptors are involved in relaxation (Talukder et al., 2002a; Ansari et al., 2007b). We 
found that NECA, a non-selective adenosine analog, produced a concentration-dependent 
contraction response in A2AKO aorta. Biphasic concentration response was observed in 
the A2AWT counterpart, suggesting the activation of more than one receptor. This data 
indicated the relaxation response produced by NECA partly involved activation of A2A 
receptors as in the absence of these receptors, only contraction was observed. 
We next used CGS 21680, which is a selective A2AAR agonist, and found that 
A2AWT aorta displayed concentration-dependent relaxation to CGS 21860, while the 
A2AKO tissue did not respond. SCH 58360, a selective A2AAR antagonist was used to 
confirm the effects of CGS 21860 in activating the A2A receptors. Relaxations to CGS 
21860 and NECA in A2AWT aorta were abolished with the use of  the SCH compound, 
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further confirming that the A2A receptor was involved in aortic relaxation. It should be 
noted that while NECA is capable of activating both A2A and A2B receptors, the A2B 
receptor is low affinity and may be activated only at higher concentrations of NECA 
(Hussain and Mustafa, 1995; Hansen et al., 2003). The role of the A2B receptor thus could 
not be ruled out.   The involvement of A2B receptors was supported by the inability of 
NECA to produce relaxation in the presence of alloxazine, a selective A2B antagonist, in 
A2A WT aorta while greater contraction was observed in the A2A KO aorta. Interestingly, 
use of SCH 58360 in the NECA response produced steep concentration-dependent 
contraction in A2A WT aorta, similar to NECA alone in A2A KO tissue. The A2B 
antagonist, alloxazine, produced contraction of a lower magnitude in A2AWT aorta 
compared to KO. To further explore the possibility of the A2B receptor contributing to 
relaxation, concentration-response to a new and selective A2B agonist BAY 60-6583 was 
obtained. At lower concentrations, no response was seen in either A2AWT or KO aorta 
while at higher concentrations (10-6 and 10-5 M) relaxation was observed in both A2A WT 
and KO tissues.  
The A1 receptor is believed to mediate contraction in the mouse aorta (Prentice et 
al., 2001; Tawfik et al., 2005). NECA has also been reported to cause contraction in 
isolated carotid rings from both A2A receptor-knockout and wild-type mice  and this 
effect was eliminated by the selective A1 receptor antagonist DPCPX (Prentice et al., 
2002). We found that incubation of tissues with DPCPX prior to obtaining NECA 
concentration-response produced a concentration-dependent relaxation response in 
A2AWT aorta and abolished the biphasic response seen with NECA alone. DPCPX also 
lowered the magnitude of NECA-mediated contraction observed in A2AKO. DPCPX is a 
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highly selective A1 receptor antagonist with a Ki of 3.9 nM compared with 130 for A2A, 
1,000 for A2B, and 4,000 nM for A3 (Klotz et al., 1998). Our data thus confirms that the 
A1 receptor mediated contraction in the A2AWT and KO aorta. 
The endothelium has been shown to play an important role in adenosine mediated 
relaxation as well as contraction and various studies have reported effects that are either 
completely endothelium-dependent/independent, or  partially endothelium-dependent in 
different isolated vessels (Rubanyi and Vanhoutte, 1985; Newman et al., 1988; Yen et al., 
1988; Ansari et al., 2007b; Ansari et al., 2007a).  Gauging the endothelial response in 
A2AWT and KO aorta was thus important. We found the endothelial response to 
acetylcholine was significantly lower in A2A KO aorta than WT.  This prompted us to 
further study the effect of the endothelium in the adenosine-mediated relaxation that was 
observed. Mechanical removal of the endothelium totally abolished the endothelium-
dependent relaxation response to acetylcholine and completely attenuated CGS 21860-
induced relaxation. This data provides evidence for the first time that A2A mediated aortic 
vasorelaxation is endothelium dependent as CGS 21860 is a selective A2A agonist.  
Studies have reported the up-regulation of the A2B receptor  in coronary arteries of 
A2AKO mice as a possible compensatory mechanism (Teng et al., 2008). To determine 
the effect of knocking out the A2A receptor on the expression of the other adenosine 
receptors in the aorta, we studied the adenosine receptor gene expression profile in 
isolated aorta. These studies showed that there was no difference in the aortic expression 
of the four adenosine receptors with the exception of the A2A receptor which was absent 
in the A2AKO as expected. Additionally, this supports our functional data in which we 
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found the selective A2B receptor agonist BAY 60-6583 produced relaxation in both 
A2AWT and KO aorta that was not different. 
In conclusion, the data provided here indicate a role for A2A receptors in 
mediating vascular relaxation in mouse aorta. The A2B receptors also contribute to aortic 
relaxation, while the A1 receptor mediates contraction. Finally, A2A mediated relaxation 
appears to be completely endothelium-dependent. The exact mechanism and signaling 

















EVIDENCE FOR THE ROLE OF THE A1 ADENOSINE RECEPTOR IN 




Poor lung function and respiratory disorders such as asthma have a positive 
correlation with the development of adverse cardiovascular events. We hypothesize that 
asthmatic lung inflammation has a systemic component and alters vascular responses 
where adenosine (AD) plays an important role through A1 adenosine receptors (A1AR). 
This study used a murine model of allergic asthma to investigate the effects of 
aerosolized AD to elevate lung AD levels, on vascular reactivity and inflammation in 
genetically modified mice, in which the A1AR was deleted (A1KO) and corresponding 
wild type mice (A1WT).  Both A1WT and A1KO mice were divided into 3 experimental 
groups: Control (CON), allergen sensitized and challenged (SEN), and SEN+ aerosolized 
AD (SEN+AD). Animals were sensitized with ragweed (200 μg, i.p.) on days 1 and 6, 
followed by 1% ragweed aerosol challenges through days 11 to 13. On day 14, SEN+AD 
groups received a single AD aerosol challenge (6 mg/ml) for 2 min, followed by 
collection of aorta and plasma on day 15. Organ bath experiments showed concentration-
dependent aortic relaxation to NECA, a non-selective adenosine analog in A1WT CON, 
which was impaired in A1WT SEN and A1WT SEN+AD. All 3 groups of A1KO mice 
showed concentration dependent relaxation to NECA, with no difference observed 
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between A1KO CON, A1KO SEN and A1KO SEN+AD. Allergen challenge caused 
systemic inflammation in allergic A1WT mice with AD aerosol further enhancing it as 
determined by inflammatory cytokines profile in plasma whereas inflammation was 
absent in all 3 groups of A1KO mice. A1WT allergic mice also had significantly higher 
airway hyper-responsiveness (P<0.05, compared to WT CON and all A1KO groups) to 
NECA, measured as Penh (enhanced pause).  In conclusion, allergic A1WT mice showed 
altered vascular reactivity, increased airway responsiveness and systemic inflammation, 
with AD aerosol further exacerbating all these effects with A1KO mice lacking these 
effects. These data suggest that A1 AR plays an important pro- inflammatory role 
systemically and is responsible for altered vasoreactivity in this model of asthma. 
 
Introduction 
Asthma, a chronic lung disease, is characterized by airway hyperreactivity and 
inflammation which result in bronchoconstriction and poor ventilation. Evidence has 
increasingly implicated adenosine in the pathophysiology of asthma (Spicuzza et al., 
2006). Increases in adenosine levels correspond to increased airway inflammation and 
tissue damage (Driver et al., 1993).  A hallmark study done in the early nineteen-eighties 
showed inhaled adenosine to be a potent bronchoconstrictor in asthmatics as opposed to 
normal subjects who showed no response (Cushley et al., 1984). Genetically modified 
mice in which adenosine deaminase (ADA), the enzyme that breaks down adenosine, was 
knocked out could not survive without exogenous administration of ADA and had severe 
pulmonary inflammation, airway hyper-reactivity and airway remodeling (Chunn et al., 
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2001; Blackburn and Kellems, 2005), indicating a strong correlation between chronic 
elevation of adenosine levels and increased lung inflammation.  
Impaired lung function is a risk factor for cardiovascular disease (Tockman et al., 
1995) and many epidemiological studies have reported that people suffering from chronic 
respiratory diseases, including asthma, have a higher incidence of cardiovascular diseases 
(Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et al., 2004; Knoflach et al., 
2005; Schanen et al., 2005). There is an association between atherosclerosis and stroke 
with reactive airway diseases. Adult-onset asthma is associated with increased carotid 
atherosclerosis in women (Onufrak et al., 2007) and subjects who had bronchial 
hyperresponsiveness to methacholine demonstrated increased carotid intima-media 
thickness (Zureik et al., 2004). Systemic inflammation in these patients, believed to be a 
consequence of airway inflammation (Jousilahti et al., 2002; Nadeem et al., 2003), may 
be one of the reasons for altered cardiovascular parameters observed (Gan et al., 2004). 
Studies done in animal models of allergic asthma have also reported enhanced systemic 
inflammation, myocardial ischemia-reperfusion injury and neutrophil recruitment to the 
myocardium (Hazarika et al., 2004, 2007). A recent study from our lab (Ponnoth et al., 
2008) has shown that allergic mice have poor vascular responses and systemic 
inflammation, with adenosine aerosol exacerbating these effects by activating A1 
adenosine receptors. 
The four adenosine receptor subtypes, i.e., the A1, A2A, A2B and A3, have different 
modulatory roles in asthma, and the cardiovascular system (Belardinelli et al., 1989; 
Mubagwa et al., 1996; Shryock and Belardinelli, 1997). Many reports suggest that the A1 
adenosine receptor is involved in direct bronchoconstrictor effects of adenosine. A1 
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receptor expression was found to be elevated in a rabbit model of asthma and the use of 
an A1 antisense nucleotide to inhibit this upregulation resulted in blunted 
bronchoconstriction to adenosine (Nyce and Metzger, 1997; Abebe and Mustafa, 1998).  
Use of a selective A1 antagonist produced  significant reduction of  airway hyper-
responsiveness in allergic rabbits by blocking these receptors (Obiefuna et al., 2005). A 
very recent study reported that the expression of A1 receptor is significantly elevated in 
airway smooth muscle in asthmatic patient (Brown et al., 2008).  Other than the effects 
on airway smooth muscle, the A1 receptor has been implicated in increased mucin 
production in human tracheal cells (McNamara et al., 2004) and in mediating monocyte 
phagocytosis (Salmon et al., 1993). All these studies suggest a strong role for the A1 
receptor in asthma, both in airway obstruction and inflammation 
A1 receptors also have systemic effects and are involved in blood pressure 
regulation (Brown et al., 2006) and  vasoconstriction (Shepherd et al., 1996; Talukder et 
al., 2002b; Hansen et al., 2003; Tawfik et al., 2005). However, the role of the A1AR in 
the control of vascular tone and systemic inflammation in an allergic model of asthma has 
not been characterized. In addition, the vascular effects of A1 receptors in response to 
exogenous adenosine challenge as an added insult in a murine model of asthma have not 
been studied previously. Therefore, this study was undertaken to investigate the effects of 
allergen challenge and inhaled adenosine on vascular reactivity and systemic 
inflammation using our murine model of asthma in A1WT and KO mice. We also 
determined the role of the A1AR in airway responsiveness by whole body 
plethysmography. Our data suggest that asthmatic A1WT mice have altered peripheral 
vascular reactivity, systemic inflammation and increased bronchoconstriction with 
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inhaled adenosine further exacerbating these effects, compared to A1KO mice, in which 
these responses were not elicited. 
 
Materials and Methods 
Animals: Balb/c mice (A1WT) 8-10 weeks old males were obtained from Harlan Sprague 
Dawley  (Indianapolis, IN) and A1KO mice were obtained from Stephen Tilley, 
Pulmonary and Critical Care, School of Medicine, University of North Carolina, Chapel 
Hill. The animals were maintained on a ragweed-free diet. All experimental animals used 
in this study were under a protocol approved by the Institutional Animal Care and Use 
Committee of West Virginia University. 
 
Animal sensitization: Sensitization was performed according to the protocol described 
earlier from this laboratory (Fan and Mustafa, 2002; Fan et al., 2003; Oldenburg and 
Mustafa, 2005; Fan and Mustafa, 2006; Mustafa et al., 2007). This model of allergic 
asthma has been shown to develop airway inflammation and airway hyper-reactivity to 
methacholine. The study comprised of six groups of animals: a) A1WT Control (A1WT 
CON); b) A1WT Allergen sensitized and challenged (A1WT SEN); c) A1WT Allergen 
sensitized and challenged further with 6 mg/ml of adenosine aerosol for 2 min on day 14 
(A1WT SEN+AD); d) A1KO Control (A1KO CON); e) A1KO Allergen sensitized and 
challenged (A1KO SEN); f) A1KO Allergen sensitized and challenged further challenged 
with 6 mg/ml of adenosine aerosol for 2 min on day 14 (A1KO SEN+AD). Experiments 
carried out previously with A1WT CON mice subject to adenosine challenge (A1WT 
CON+AD) showed that this group was not different from A1WT CON and, hence, this 
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group was not included for further experimentation. Mice were sensitized on days 1 and 6 
with i.p. injections of ragweed allergen (Greer Laboratories, Lenoir, NC), 200 µg per 
dose with 200 µL Imject Alum (Pierce Laboratories, Rockford, IL). Non-sensitized 
control animals received only the Imject alum with the same volumes. 10 days after 
sensitization, the mice were placed in a Plexiglas chamber and challenged with 1% 
aerosolized ragweed or with 0.9% saline as a control, using an ultrasonic nebulizer 
(DeVilbiss Somerset, PA) for 20 minutes both in the morning and afternoon for three 
consecutive days. The aerosolization of allergen was performed at a flow rate of 2 
mL/min, and the aerosol particles had a median aerodynamic diameter of less 4 µm (De 
Vilbiss).  
Acute elevations in lung adenosine levels were produced experimentally by 
adenosine inhalation (6 mg/ml for 2 min on day 14) to SEN+AD group to further enhance 
allergen-induced effects. This dose was chosen based on our previous studies in this 
model (Fan and Mustafa, 2002; Fan and Jamal Mustafa, 2006). Adenosine inhalation in 
this model has been shown to enhance allergen-induced airway inflammation and airway 
hyper-reactivity to adenosine (or its analog NECA) (Fan and Mustafa, 2002; Fan et al., 
2003; Fan and Mustafa, 2006). ADA-deficient mice having sustained and chronic 
elevations in lung adenosine levels have also been shown to have similar features (Chunn 
et al., 2001). We chose 24 hr post-adenosine inhalation for our current studies based on 
an earlier study from our lab which showed maximum eosinophilic inflammation in 
airways after 24 hr of adenosine inhalation (Fan and Mustafa, 2006), which is a hallmark 
of asthmatic inflammation. CON and SEN groups received only saline on day 14. 
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Twenty-four hours after the last challenge, animals were sacrificed for collection of aorta 
and blood for further experiments. 
 
Preparation of isolated mouse aorta and isometric force measurement 
Mice were sacrificed by anesthesia with pentabarbitol sodium (65 mg/kg, i.p.) followed 
by thoracotomy and removal of aorta that was then cut transversely into 3-4 mm rings. 
The rings were mounted vertically between two stainless steel wire hooks and then 
suspended in 10 mL organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit 
buffer (pH 7.4) containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 25 mM NaHCO3, 11 mM glucose and 2.5 mM CaCl2 was maintained at 37°C 
with continuous bubbling of 95% O2 and 5% CO2. For measurement of isometric force 
response, aortic rings were equilibrated for 90 min with a resting force of 1g that has 
been used earlier in our laboratory (Tawfik et al., 2005; Ansari et al., 2007b) and change 
of the bathing solution at 15 min interval. At the end of equilibration period, tissues were 
contracted with 50 mM KCl to check the contractility of individual aortic rings twice 
which were washed out with Krebs-Henseleit buffer. Aortic rings were then constricted 
with phenylephrine (PE, 10-7 M) to obtain a steady contraction and changes in tension 
were monitored continuously with fixed range precision force transducer (TSD, 125 C, 
BIOPAC system) connected to the differential amplifier (DA 100B, BIOPAC system). 
The data were recorded using MP100, BIOPAC digital acquisition system and analyzed 





After equilibration, the responsiveness and stability of individual rings were checked by 
successive administration of submaximally effective concentration of PE (10-7 M). The 
integrity of the vascular endothelium was assessed pharmacologically by acetylcholine 
(10-7 M) to produce relaxation of PE pre-contracted rings. Aortic rings were then washed 
several times with Krebs-Henseleit solution, and allowed to equilibrate for 30 min before 
the experimental protocol began.  
 
Experimental protocol 
The concentration-response curves (CRCs) for NECA (10-9 -10-5 M) were run parallel in 
aortic rings from all the groups. In all cases, NECA was added to yield the next higher 
concentration only when the response to the earlier dose reached a steady state. 
Contraction/relaxation responses were expressed as a percentage increase/decrease in the 
contraction with respect to PE (alone) in response to each concentration of agonist used. 
 
Assessment of systemic inflammation 
Mice were euthanized by pentobarbitone sodium (65 mg/mL, i.p.), followed by collection 
of blood by cardiac puncture in heparinized syringes. The blood collected from different 
groups was centrifuged at 800 g for 10 min at 4° C and the resulting plasma was used for 
cytokine assays. 
Multiplex cytokine assay: Cytokine assay of IL-5, TNFα and IL-13 in the plasma was 
measured by a commercial kit from Linco Research (St. Charles, Missouri) using the 
Luminex 200 system (Luminex Corp., Austin, Tx), which is a multianalyte bioassay 
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detection system capable of performing up to 100 assays simultaneously in a single 
microtiter plate well. This system uses polystyrene microspheres internally dyed with red 
and infrared fluorophores that can be individually identified. The fluorescent 
microspheres were coated with capturing antibodies specific for different chemokines. 
The chemokine-captured beads after incubation with the sample were then mixed with 
phycoerythrin-conjugated detection antibodies to form immune complexes. Following 
incubation, washing and acquisition of fluorescence data, the concentration results were 
generated in graphical format using the standard curve generated for each cytokine. 
Results were expressed in pg/mL. 
 
Airway responsiveness to Methacholine (MCh) and NECA 
The airway responsiveness was assessed by whole body plethysmography using the 
chambers obtained from Buxco Inc. (Max II; Buxco Systems, Wilmington, NC). This 
system enables the measurement of airway obstruction using a dimensionless parameter 
called enhanced pause or Penh. Higher the Penh values, greater is the airway obstruction. 
Penh has been shown to correlate with airway resistance and dynamic compliance 
(Justice et al., 2001). Unrestrained mice were placed in individual Plexiglas chambers 
twenty four hours after the last allergen challenge and subjected to increasing 
concentrations of MCh (1.5-48.0 mg/ml) to obtain concentration-responses. In case of 
SEN+AD groups, this was 24 hours post adenosine aerosolization. Concentration-
responses to NECA were performed 24 hours post the MCh experiment. After obtaining 
baseline and vehicle Penh values, mice were exposed to increasing concentrations of 
NECA (23.44-750 µg/ml) via the Buxco aerosol delivery system (version 1.5; Buxco, 
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Wilmington, NC). Each concentration of NECA was aerosolized for 2 minutes and the 
Penh readings were recorded for 5 minutes to establish a dose-response relationship. The 
next dose was not administered until the mice had returned to baseline Penh levels. 
Airway responsiveness was normalized to the vehicle control (normal saline) and 
expressed as a percentage increase in Penh. 
 
Drugs used 
Acetylcholine, adenosine and phenylephrine were dissolved in distilled water. 5’-N-
ethylcarboxamidoadenosine (NECA) was dissolved in 100% DMSO as a 10 mM stock 
solution for vascular reactivity experiments. The final concentration of DMSO in organ 
bath  (bath volume: 10 mL) had no effect by itself on the aortic rings (Ansari et al., 
2007b). For Penh responses, MCh was dissolved in 0.9% saline and NECA was dissolved 
in 100% ethanol to create a stock solution from which subsequent dilutions were made 
with 0.9% saline. Unless stated otherwise, all chemicals were of the highest grade 
available and were purchased from Sigma Chemicals (St. Louis, MO). 
 
Statistical Analysis 
The data were expressed as mean± SEM. Comparisons among different groups were 
analyzed by ANOVA (analysis of variance) followed by Tukey’s multiple comparison 
test/ Bonferroni’s selected pair test. Comparison between two groups was assessed by 
unpaired t-test. A p value of less than 0.05 was considered as the level of significance. 




Systemic inflammation in control, allergic and adenosine aerosolized allergic mice 
Table 5.1 shows the multiplex cytokine profile in all the groups. Allergen challenge 
significantly increased plasma levels of inflammatory cytokines IL-5 and IL-13 in A1WT 
SEN as compared to A1WT Con and all groups of A1KO mice. Allergen sensitized and 
challenged A1WT mice exposed to adenosine aerosol (SEN+AD) had the highest level of 
the pro-inflammatory cytokines compared to other groups. Other cytokines in the panel 
were either undetectable or not different among the groups (data not shown). These data 
suggest activation of the A1 receptor has pro-inflammatory effects. 
 
Vascular reactivity in control, allergic and allergic + adenosine groups 
The aortic relaxation/contraction responses to NECA were studied in all 6 groups. Organ 
bath data showed a concentration dependent relaxation response to NECA in A1WT 
CON, while aortic relaxations were impaired in A1WT SEN aorta with a maximum 
relaxation of 7% (Fig 5.1 A). NECA failed to elicit any relaxation response in SEN+AD; 
it produced a concentration dependent contractile response, with a maximum contraction 
of 35% at 10-6 M (Fig 5.1 A).  In contrast, all 3 groups of KO mice showed concentration-
dependent relaxation and there was no difference in the responses between the groups 
(Fig 5.1 B). These data show that allergen sensitization and challenge altered the vascular 
reactivity with adenosine aerosol further exacerbating it in allergic A1WTmice, indicating 
that the A1 receptor was responsible for the low adenosine-mediated vascular relaxation 
observed. Comparison between respective groups of SEN and SEN+AD WT and KO 
groups are shown in figures 5.2 and 5.3. 
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Endothelial function in control, allergic and allergic + adenosine groups 
Figure 5.4 shows the endothelial response to ACh in all experimental groups. A1WT SEN 
(~39%) and SEN+AD (~38%) groups had significantly lower (P<0.01) endothelial 
response to acetylcholine compared to WT controls (~65% relaxation). There was no 
difference in endothelial response between any group of A1KO mice and between the KO 
groups and A1WT CON; however A1KO SEN and A1KO SEN+ AD had significantly 
higher endothelial relaxation than A1WT SEN and A1WT SEN+ AD groups (P<0.05) 
These data show that allergen challenge probably led to endothelial dysfunctional in 
allergic A1WT mice. 
 
Airway responsiveness to Methacholine (MCh) and NECA 
The airway responsiveness to MCh (Fig 5.5) was assessed and there was no difference 
between control A1WT and KO mice. All groups of sensitized mice WT and KO had 
significantly increased airway response to MCh compared to respective controls but there 
was no difference between sensitized A1WT and KO mice.  Next, the response to NECA 
was assessed (Fig 5.6). Although baseline Penh values for control A1WT (284.05 ± 65.4) 
were higher than A1KO (180.36 ±22.52), the difference was not statistically significant. 
However, allergic A1WT SEN and A1WT SEN+AD mice had significantly higher airway 
responsiveness, with the response being highest in the A1WT SEN+AD group. In 
contrast, A1KO SEN and SEN+AD groups had comparable response to A1KO CON 
group. These data indicate that adenosine mediated hyper-responsiveness is mediated 
through the A1 receptor.  
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Table 5.1: Systemic inflammation as assessed by levels of inflammatory cytokines in 
plasma of A1WT  and A1KO control (CON), allergic (SEN) and adenosine aerosolized 
allergic (SEN+AD) mice; Values are expressed as Mean ± SEM (n=4-8). *P<0.05 
compared to A1WT CON; #P<0.05 compared to A1WT SEN.  
 
 
CON SEN SEN+AD INFLAMMATORY 
MARKER (pg/ml) A1WT A1KO A1WT A1KO A1WT A1KO 
IL-5 3.35±0.14 3.98±0.93 8.22±1.65* 4.078±0.57 11.12±1.5* 3.88±1.50 
IL13 27.44±5.57 UNDETECTED 45.41±9.91* UNDETECTED 170±49.97*# UNDETECTED




















Figure 5.1 Concentration-response curves for NECA-mediated relaxation/contraction in 
A1WT (A) and A1KO (B) with control (CON), allergic (SEN) and adenosine aerosolized 
allergic (SEN+AD) groups. Values are expressed as mean ± SEM (n=4). On the ordinate, 
positive and negative values indicate relaxation and contraction, respectively. *P<0.05 as 
compared to CON; $ P<0.05 as compared to SEN. 
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Figure 5.2 Comparison between A1KO and A1WT sensitized mice. Values are expressed 
as mean ± SEM (n=4). On the ordinate, positive and negative values indicate relaxation 
and contraction, respectively. *P<0.05 
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Figure 5.3 Comparison between A1KO and A1WT SEN+AD mice. Values are expressed 
as mean ± SEM (n=4). On the ordinate, positive and negative values indicate relaxation 
and contraction, respectively. *P<0.05   
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Fig 5.4  Endothelial response to ACh in CON, SEN and SEN+AD A1WT and A1KO 
mice. A1WT SEN and SEN+AD groups were significantly different from A1WT CON 























































Figure 5.5 Airway responsiveness to MCh in A1KO and A1WT mice. Values are 
expressed as mean ± SEM (n=4-8). On the ordinate, airway response is expressed as % of 
the vehicle. *P<0.05 A1WT SEN and SEN+AD compared to A1WT CON; # P<0.05 
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Figure 5.6 Airway responsiveness to NECA in A1KO and A1WT mice. Values are 
expressed as mean ± SEM (n=4-8 ). On the ordinate, airway response is expressed as % 
of the vehicle. *P<0.01 compared to A1KO CON; $P<0.01 compared to A1KO SEN; #P< 
0.05 compared to A1KO SEN+AD; %P<0.05 compared to A1WT SEN, @P<0.05 
compared to A1WT CON. 
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The principal finding of the present study is that allergic A1WT mice had 
systemic inflammation, increased airway responsiveness and impaired vasorelaxation to 
NECA, a non-selective adenosine analog. These outcomes were further aggravated after 
acute adenosine aerosol challenge in these mice. Responses in allergic A1KO mice were 
not different from non-allergic wild type controls, indicating that the A1 adenosine 
receptor was responsible for alterations in vascular reactivity, airway hyper-
responsiveness and increased inflammation. Administration of NECA caused increased 
airway responsiveness in allergic A1WT mice which was absent in corresponding A1KO 
mice. Endothelium was found to be dysfunctional in allergic A1WT mice compared to 
non-allergic A1WT controls, while both allergic and non-allergic A1KO mice had no 
difference in endothelial responses.  
Adenosine is chronically elevated in asthmatic lungs (Mann et al., 1986b; Mann et 
al., 1986a; Driver et al., 1993). Evidence indicates adenosine may be involved in the 
release of inflammatory mediators in the lung and systemic circulation by acting on its 
receptors present on different cells including mast cells, eosinophils, neutrophils and 
other inflammatory cells (Driver et al., 1991; Fan and Jamal Mustafa, 2006; Nadeem and 
Mustafa, 2006; Spicuzza et al., 2006) and can thus contribute to the severity of lung 
inflammation. Adenosine is a known bronchoprovocant (Cushley et al., 1983) and 
experimentally induced temporary elevations in lung adenosine levels through inhalation 
of adenosine (resulting from breakdown of adenosine 5'-monophosphate) cause an 
increase in infiltration of eosinophils in patients with asthma (van den Berge et al., 2004).  
A recent study from our lab has also shown increased release of inflammatory cell 
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markers in the lung and plasma after inhalation of adenosine aerosol in allergic mice (Fan 
and Mustafa, 2002).  However, the systemic effects of such an inhalation with respect to 
involvement of specific adenosine receptors have not been studied previously. Adenosine 
aerosol in human asthmatics causes increased release of neutrophil chemotactic factor in 
serum (Driver et al., 1991). These studies suggest that adenosine enhances the release of 
systemic inflammatory mediators from inflammatory cells 
Systemic inflammation has been reported previously in human asthmatics and 
animal models of asthma (Jousilahti et al., 2002; Hazarika et al., 2004). Neutrophils and 
eosinophils are increased in bronchoalveolar lavage and blood in a murine model of 
asthma (Hazarika et al., 2007). Systemic inflammatory markers have also been shown to 
be elevated in patients with asthma and in allergic mouse model of asthma after 
adenosine aerosol challenge. (Driver et al., 1991; Fan and Jamal Mustafa, 2006).  Based 
on the findings of these studies, we investigated the cytokine profile in systemic 
circulation in allergic A1WT and A1KO mice. We found that while allergic A1WT mice 
had significantly elevated levels of pro-inflammatory cytokines, allergic A1WT mice 
exposed to acute adenosine aerosol had further exacerbation of systemic inflammation as 
evidenced by the finding that several pro-inflammatory cytokines levels (IL-13, MCP-1, 
and TNF-α) were increased most in this group. In A1KO mice, both allergic and control 
groups either had undetected or non-significant levels of inflammatory markers, 
suggesting the absence of the A1 receptor was related to lower inflammation. From the 
mediator profile, IL-13 was significantly higher in the plasma of A1WT SEN mice, with 
adenosine challenge exacerbating it even further. IL-13 is an important mediator in 
asthma and has been implicated in lung inflammation, airway remodeling and airway 
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hyperreactivity (Grunig et al., 1998; Lowry et al., 2008). Adenosine and IL-13 interact 
positively, with each increasing the levels of the other in studies done with asthmatic 
mice (Blackburn et al., 2003). IL-13 and adenosine thus are important in lung 
inflammation but their role in systemic inflammation is not known. Our data suggest a 
pro-inflammatory role for IL-13 and adenosine mediated systemic inflammation via the 
A1 receptors. 
Asthma has been associated with an increased incidence of negative 
cardiovascular outcomes (Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et 
al., 2004; Knoflach et al., 2005). While asthmatic inflammation is believed to responsible 
for the development of these cardiovascular effects, there is little information linking the 
two, especially in relation to the vascular effects of specific adenosine receptors. In the 
present study, NECA, a non-selective adenosine analog produced a concentration- 
dependent vasorelaxation in control A1WT mice, which was impaired in allergic A1WT 
mice. Vascular reactivity to NECA was further altered in aorta of allergic A1WT mice 
that had received aerosolized adenosine. In contrast, NECA produced a concentration-
dependent vasorelaxation response in allergic and non-allergic A1KO groups. These 
findings strongly suggest that the A1 receptor indeed is responsible for poor vascular 
responses in allergic mice. 
In a recent study from this laboratory, we found that allergic mice had lower 
endothelial relaxation suggesting that allergen exposure and development of allergic 
asthma somehow resulted in endothelial dysfunction (Ponnoth et al., 2008). In the present 
study, we observed that there was no difference in the endothelial response between 
control and allergic A1KO mice as opposed to significantly lower endothelial relaxation 
 89
in allergic A1WT mice compared to A1WT controls. The exact cause for this dysfunction 
is not clear but it could possibly be due to the A1 receptor-mediated increase in systemic 
inflammatory cytokines. These inflammatory cytokines are known to suppress eNOS and 
nitric oxide production (Cardaropoli et al., 2003; Li et al., 2004). For the first time, the A1 
receptor specifically has been shown to affect the endothelium functionality in allergic 
mice. Further studies are required to delineate the exact mechanism for the role of the 
A1AR in alteration of endothelial function especially the signaling pathways that may be 
involved.  
Whole body plethysmography has been used previously to determine the extent of 
airway responsiveness and as an index of airway obstruction (Drazen et al., 1999; Fan 
and Mustafa, 2002; Fan et al., 2003; Oldenburg and Mustafa, 2005). We used this method 
to determine the differences between A1WT and KO responses to MCh and NECA. MCh 
produced higher airway responsiveness in both A1WT and KO sensitized animals 
compared to controls. No difference was observed between A1WT and KO mice.  
However, the response to the non-selective adenosine analog NECA was different 
between A1KO and WT mice. There was no difference in NECA-mediated airway 
response in all three groups of A1KO mice, while A1WT SEN mice had significantly 
higher responses.  The highest response was observed in A1WT SEN+AD, which was 
significantly different from all other study groups.  The A1 receptor has been implicated 
in the direct adenosine-mediated bronchoconstrictor response (Nyce and Metzger, 1997; 
Abebe and Mustafa, 1998) and  a selective A1 antagonist produced  significant reduction 
of  airway hyper-responsiveness in allergic rabbits by blocking these receptors (Obiefuna 
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et al., 2005).  Our data supports a role for A1 receptor-mediated airway 
hyperresponsiveness and also shows that adenosine challenge exacerbates the response.  
In conclusion, our findings provide evidence for the first time that the A1 
adenosine receptor mediates alterations in systemic parameters (inflammation, lower 
endothelial response and impaired vasorelaxation) and airway hyper-responsiveness as a 
result of allergen exposure and adenosine aerosol challenge in sensitized mice. 
Understanding the exact contribution of adenosine and adenosine A1 receptor mediated-
systemic effects with respect to mechanisms and signal transduction would provide an 
important tool in the prevention of systemic inflammation and harmful systemic side 
effects in designing therapies for asthma. Ultimately, this could be beneficial in lowering 







  The work presented in this dissertation establishes that asthma has 
detrimental effects beyond lungs and airways in allergic mice. Systemic inflammation, 
endothelial dysfunction and altered vascular reactivity appear to be associated with 
asthma. Adenosine plays an important role in these effects and exogenously administered 
adenosine to increase the lung levels experimentally beyond the allergen exposure 
exacerbates observed outcomes.   
Specific adenosine receptors are involved in the vascular responses seen, with 
different receptors modulating beneficial and detrimental effects. Vascular A2A and A2B 
receptors are down-regulated in allergic mice, and this was confirmed with the use of the 
specific receptor antagonists. To get a better insight into the role of A2A receptors on 
aortic tone, vascular responses to various adenosine analogs were studied in A2A receptor 
knock-out and wild type mice that were non-allergic.  
In vitro aortic relaxation in A2AWT mice was a biphasic response to NECA, a 
non-selective adenosine analog, while the response in A2AKO tissue was concentration-
dependent contraction. This indicated the possibility that the absence of A2A receptor as 
being responsible for contraction. A2AKO mice also had lower endothelial relaxation than 
their wild-type counterparts, which suggested that relaxation through A2A receptors 
occurred via an endothelial dependent mechanism. Use of the A1 antagonist (DPCPX) 
increased the relaxation in A2AWT mice while the contraction observed in A2AKO mice 
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was reduced although relaxation was still absent. This again underscored a role for the 
A2A receptor in relaxation while confirming that the A1 receptor was responsible for 
adenosine-mediated contraction.  These studies determined that the A2A receptor mediates 
vasorelaxation in the aorta in conjunction with the A2B receptor.  
The next aim of the study was to determine the exact role of the A1 receptor in the 
allergic model. The reason for focusing on the A1 receptor came about from the initial 
study when it was found that the use of DPCPX (selective A1 receptor antagonist) 
restored aortic relaxation in allergic mice comparable to non-allergic controls. The A1 
receptor was also found to be up-regulated in the aorta from allergic mice further 
subjected to adenosine aerosol.  
Genetic knock-out mice were used to study and confirm the involvement of A1 
receptor. Data showed that the allergic A1WT mice had lower adenosine-mediated aortic 
relaxation, significantly higher levels of inflammatory markers in the plasma and 
increased airway responsiveness. These outcomes were exacerbated in allergic A1WT 
mice that had received exogenous adenosine as a single aerosol inhalation. In contrast, no 
impairment in adenosine-mediated vascular responses were observed in A1KO (allergic 
and non-allergic controls) aortic tissue. There were significantly lower (or undetectable) 
levels of inflammatory markers and lower airway responsiveness to NECA in A1KO 
mice. In fact, there was no difference between allergic A1KO and control A1KO mice.  
These data implicate the A1 receptor as having deleterious systemic and airway effects in 
allergic mice. The systemic effects appear to be the result of inflammation.  However, the 
exact signaling mechanism(s) of the A1 involved in translation of airway inflammation to 
the observed systemic outcomes is not known and remains to be studied. 
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Future Direction 
The next step in this model of asthma would be to define the adenosine receptor 
signaling mechanisms involved. Our preliminary data show that asthmatic mice have 
both lung as well as systemic inflammation. It is important to have a better understanding 
of this correlation and the possible signaling pathways involved. Based on the data in this 
dissertation that shows highest levels of IL-13 in allergic mice, and review of literature 
which has established a close relationship between IL-13 and adenosine in lung 
inflammation, the next focus could the potential role for this inflammatory cytokine as an 
intermediary signaling molecule, both in asthma and cardiovascular disease.  
IL-13 is an important mediator in asthma and has been implicated in lung 
inflammation and airway remodeling. It is a product of mast cell degranulation and is 
also released from T-helper 2 (Th2) cells. Adenosine and IL-13 interact with each other 
in a positive feedback in studies done with asthmatic mice (Blackburn et al., 2003).These 
authors found that IL-13 caused a progressive increase in adenosine accumulation, 
inhibited the activity of adenosine deaminase, and augmented the expression of the A1, 
A2B, and A3 adenosine receptors. Their findings suggest that adenosine signaling 
contributes to and influences the severity of IL-13 induced tissue responses.  
IL-13 signaling occurs through the Janus kinase (JAK)/signal transducer and 
activator of transcription (STAT) pathway. This cytokine acts on its receptor (via JAK-1) 
and leads to phosphorylation of STAT6, which induces the transcription of several genes 
including 5-lipoxygenase (LO).  5-LO, via the arachidonic acid pathway, produces 
inflammatory leukotrienes (LTs) which are very important mediators of IL-13 induced 
lung injury. Recent studies have also suggested a pro-atherosclerotic role for LTs with 
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LTB4 acting as a potent leukocyte chemoattractant that amplifies inflammation at 
atherosclerotic sites (M.Back et al., 2005). 
Other than LTs, studies in asthma have shown that IL-13 also induces vascular 
endothelial growth factor (VEGF) from human airway smooth muscle cells, mast cells, 
epithelial cells and macrophages (Faffe et al., 2006). In fact, IL-13 and VEGF act on each 
other in positive feedback loops.  VEGF and VEGF receptor inhibitors reduce lung 
inflammation and airway hyper-reactivity in asthma (Faffe et al., 2006). This study also 
found that over expression of VEGF enhances Th2-mediated sensitization and 
inflammation. Studies involving human atherosclerosis have noted that VEGF is thought 
to play a pro-atherosclerotic role. VEGF is an angiogenic factor. It induces migration and 
proliferation of endothelial cells and enhances vascular permeability. It has been reported 
that human coronary atherosclerotic plaques were positive for VEGF mRNA but not so in 
normal arterial tissues (Inoue et al., 1998).   
IL-13 and IL-4 act synergistically with TNF-α to increase eotaxin levels in the 
lungs. Eotaxin increases lung eosinophilia in asthma and is very important in 
amplification of eosinophilic inflammation. Though eosinophilia is considered to be a 
characteristic hallmark of asthmatic inflammation, eosinophils are not found in any 
significant amounts in atherosclerotic lesions. However, eotaxin may have a novel role in 
atherosclerosis that does not involve eosinophils. Haley et al.  have reported that eotaxin 
and its receptor, CCR3, were overexpressed in the inflammatory infiltrate of human 
atheroma (Haley et al., 2000). CCR3 was predominantly expressed on macrophages and 
they suggest eotaxin may participate in mast cell activation or recruitment.  
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Data in this dissertation show that systemic levels of IL-13 are increased 
significantly in allergic A1WT mice compared to non-asthmatic controls. Interestingly, 
allergic A1KO did not have any increase in IL-13, suggesting a role for the A1 receptor. 
The next step would be to determine if IL-13 does, in fact, have a role in vascular 
inflammation and the signaling mechanism involved. Ultimately, understanding the 
signaling pathway (s) involved would lead to uncovering of the translational mechanism 
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The relaxation response to NECA was calculated at two different concentrations of 
phenylephrine (PE) used to pre-contract tissues. This was done to determine the 
concentration of PE to be used for experiments. There was no difference in NECA 



























































The relaxation response to adenosine was calculated at two different concentrations 
phenylephrine used to pre-contract tissues. This was done to determine the concentration 
of PE to be used for experiments. There was no difference in adenosine mediated 































































The endothelial response to acetylcholine was determined at two different concentrations 
phenylephrine (PE) used to pre-contract tissues. This was done to determine the 
concentration of PE to be used for experiments. There was no difference in adenosine 
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Preliminary experiments (airway responsiveness and vascular reactivity) were carried out 
with ovalbumin-sensitized and challenged A2AWT and A2AKO mice that had also 
received aerosolized adenosine challenge. A2AKO mice had increased airway 
responsiveness as seen from the Penh data and reduced aortic relaxation to NECA 
compared to wild-type counterparts.  However, adenosine mediated aortic vascular 
responses in naïve (non-allergic) mice were not known, which led to studying of vascular 
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Level of inflammatory cytokines in bronchoalveolar lavage fluid was measured in control 
(CON), ragweed sensitized (SEN) and ragweed sensitized +aerosolized adenosine Balb/c 
mice to determine the difference in lung inflammation. Sensitized mice that had received 
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